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In a previous expression microarray study, IL23A was identified as a putative target 
gene of RUNX3, a transcription factor and a prominent gastric tumour suppressor. 
IL23A encodes for the unique subunit of IL-23, a heterodimeric cytokine necessary 
for pathogen surveillance in the gut. Using reporter gene and promoter occupancy 
assays, together with ectopic expression and RNAi knockdown studies, IL23A was 
demonstrated to be a genuine target gene of RUNX3 in gastric epithelial cells. 
Furthermore, RUNX3 is a critical requirement for the synergistic induction of IL23A 
by TNF- and Helicobacter pylori – two key inflammatory signals strongly linked to 
human gastric carcinogenesis. In the presence of these stimuli, IL23A is robustly 
expressed and secreted by gastric epithelial cells, albeit not in its normal 
heterodimeric form. Lastly, stimulation of human PBMC-derived T cells with IL23A-
containing supernatant revealed functions for this protein in promoting T cell 
proliferation and IFN- production. Together, these data indicate that RUNX3 
functions as a tumour suppressor in part by modulating gastric inflammation and 
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1.1 The RUNX family members 
Runt-related (RUNX) proteins are key developmental transcriptional 
regulators whose dysregulation are often associated with human cancers (Ito, 1999). 
The founding member of the RUNX gene family is runt, a Drosophila “pair-rule” 
gene that controls segmentation in embryos and is required for neurogenesis and sex 
determination (Duffy and Gergen, 1991; Duffy et al., 1991; Ingham and Gergen, 
1988; Kania et al., 1990). Subsequently, RUNX genes are found in phylogenetically 
diverse organisms including nematode worm Caenorhabditis elegans, zebrafish 
Danio rerio and mammals (Sullivan et al., 2008). Despite their evolutionary 
divergence, the DNA-binding domain for these proteins remains highly conserved 
even in the most basic metazoan, indicating that RUNX proteins play fundamental 
role in cell biology (Sebe-Pedros et al., 2011; Sullivan et al., 2008).  
Mammalian RUNX was originally discovered by independent groups to be a 
nuclear factor that binds to the transcriptional enhancers in polyomaviruses and 
murine leukemia viruses (Kamachi et al., 1990; Speck et al., 1990). Shortly after, 
RUNX gene was found to be frequently targeted by t(18;21) chromosome 
translocation in human acute myelogenous leukemia (Miyoshi et al., 1991; Miyoshi et 
al., 1997). Due to the concurrent discovery of RUNX genes by various groups, RUNX 
genes were given a variety of names including polyomavirus enhancer-binding-
protein-2 alpha (PEBP2), core binding-factor alpha (CBF) and acute myelogenous 
leukemia (AML). Eventually, the term ‘RUNX’ was adopted to refer to genes 
encoding the runt-related proteins (van Wijnen et al., 2004).  
To date, three mammalian runt-related genes have been characterised; RUNX1 
(AML1/CBFA2/PEBP2B), RUNX2 (AML3/CBFA1/PEBP2A), and RUNX3 
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(AML2/CBFA3/PEBP2C) (Ito, 2004). A high level of sequence and structural 
homology is shared among all three members which include an enormously conserved 
128 amino acid Runt domain and a five amino-acid VWRPY domain (Coffman, 2003; 
Ito, 1999; Levanon et al., 2003; Rennert et al., 2003). The high degree of sequence 
similarity suggests the crucial importance of these domains to the function of RUNX 
proteins. The amino-terminal Runt domain is critical for RUNX proteins to function 
as transcription factors as it confers sequence specific DNA-binding and dimerisation 
with their non DNA-binding subunit, core-binding factor beta (CBF) (Kamachi et 
al., 1990). Although the Runt domain alone is able to bind DNA, its binding affinity 
and hence transcriptional activity are fully activated only when dimerised with CBF 
(Ogawa et al., 1993a; Ogawa et al., 1993b). The carboxyl-terminal VWRPY motif is 
responsible for repressing the transcriptional activity of RUNX proteins by acting as a 
platform to recruit co-repressors including transducing-like enhancer (TLE)/Groucho 
(Aronson et al., 1997; Imai et al., 1998; Levanon et al., 1994). In spite of these 
similarities, each RUNX gene product has seemingly distinct biological functions, 










1.2 The pleiotropic roles of RUNX genes in development and diseases 
1.2.1 RUNX1 in haematopoiesis and leukaemia 
Amongst the RUNX genes, Runx1 is the most studied gene in both mouse and 
human. RUNX1 is a master regulator of haematopoiesis and its functional 
dysregulation often leads to leukaemia. Homozygous deletion of Runx1 in mice 
obliterated the fetal liver haematopoiesis and impaired the formation of vascular 
capillaries, demonstrating the importance of Runx1 in definitive haematopoiesis 
(Okada et al., 1998; Okuda et al., 1996; Takakura et al., 2000; Wang et al., 1996).  
Subsequently, it was discovered that Runx1 is essential for the emergence of 
hematopoietic stem cells (HSCs) from the hematogenic endothelial clusters in the 
embryonic aorta-gonad-mesonephros (AGM) region (North et al., 1999; Yokomizo et 
al., 2001). These discoveries highlight the critical role of Runx1 in the initiation of the 
hematopoietic system. In adult mice, Runx1 is essential for terminally differentiation 
of the multi-lineage hematopoietic cells. Conditional ablation of Runx1 in adult mice 
led to defective megakaryocytes, T- and B-lymphocyte development (Growney et al., 
2005; Taniuchi et al., 2002). During T cell development,  Runx1 is involved in the 




 double negative immature thymocytes via 
direct binding to two Runx binding motifs in the CD4 silencer (Taniuchi et al., 2002).  
In human, RUNX1 is one of the most frequently disrupted genes in acute 
myelogenous leukaemia (AML) (Look, 1997; Osato, 2004; Speck and Gilliland, 
2002). Classical chromosomal translocations that inhibit RUNX1’s function through 
the generation of chimeric proteins are prevalent in various types of leukaemia 
including acute myelogenous leukaemia (AML1-ETO), chronic myelogenous 
leukaemia (AML1-Evi1) and childhood acute lymphoblastic leukaemia (TEL/AML1) 
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(Golub et al., 1995; Mitani et al., 1994; Nucifora et al., 1993). Moreover, loss-of-
function RUNX1 mutations were also found in both sporadic and familial cases which 
predispose the patients to the development of acute myeloid leukaemia (Osato et al., 
1999; Song et al., 1999). Interestingly, gain-of-function mutations caused by 
amplification of the RUNX1 locus and increased in its promoter activity are also 
leukemogenic (Niini et al., 2000; Wotton et al., 2002). Thus, it appears that RUNX1 
expression has to be precisely regulated to prevent leukaemia. Taken together, 
RUNX1 is a global regulator of embryonic and adult haematopoiesis whose 
dysregulation is strongly link to leukemogenesis. 
  
1.2.2 RUNX2 in bone development 
RUNX2 is a central regulator of bone development in mammals and 
vertebrates. Genetic ablation of Runx2 in mice resulted in impaired osteoblasts 
maturation and osteogenesis, thereby leading to complete lack of bone tissue 
formation (Komori et al., 1997; Otto et al., 1997). Consistent with this phenotype, 
Runx2 regulates the expression of a major set of osteoblast-related genes including 
osteocalcin, osteopontin, collagenase 3 and MMP9 that define the osteoblast lineage 
from mesenchymal stem cells (Ducy et al., 1999; Ducy et al., 1997; Geoffroy et al., 
1995; Jimenez et al., 1999; Pratap et al., 2005). While Runx2
-/-
 mice died from 
asphyxiation due to systematic lack of ossification, including the absence of ribs, 
Runx2
+/-
 mice displayed skeletal abnormalities that are characteristic of human 
heritable skeletal morphorgenesis disorder, cleidocranial dysplasia (Lee et al., 1997; 
Mundlos et al., 1997). Indeed, loss-of-function mutations of RUNX2 are found in 




Similar to the other two Runx transcription factors, Runx2 displays anti-
proliferative function in normal osteoprogenitors and pre-osteoblasts by affecting cell 
cycle progression at G1 phase, implicating a role in stringent cell growth control in 
this cell types (Galindo et al., 2005; Pratap et al., 2003; Teplyuk et al., 2008; Young et 
al., 2007b; Zaidi et al., 2007). Paradoxically, unscheduled expression of RUNX2 has 
also been reported in a subset of osteosarcomas (Blyth et al., 2005; Pratap et al., 
2006). The robust expression of RUNX2 in osteosarcomas correlates with metastasis 
and poor chemotherapy response by controlling genes linked to cell motility and 
adhesion (Lucero et al., 2013; Pereira et al., 2009; Sadikovic et al., 2010; San Martin 
et al., 2009; van der Deen et al., 2012). Furthermore, overexpression of RUNX2 is not 
restricted to osseous cancer but also observed in nonosseous cancers including 
prostate and breast cancers indicating that RUNX2 may have an oncogenic function in 
tumourigenesis (Akech et al., 2010; Das et al., 2009; Leong et al., 2010; Pratap et al., 
2009; Pratap et al., 2011; Pratap et al., 2008; van der Deen et al., 2010). 
 
1.2.3 RUNX3 in neuron and lymphocyte development 
RUNX3 is often considered the most primitive forms among all mammalian 
RUNX family members, as it retains the highest level of mammalian wide 
interspersed repeats (MIR), which are elements enriched in most ancient genes 
(Bangsow et al., 2001). It is also the smallest member that possesses all the structural 
hallmarks common to the RUNX family members (Bangsow et al., 2001). Unlike 
RUNX1 and RUNX2 which play fundamental roles in a restricted number of organs, 
RUNX3’s roles appear more pleiotropic. In mouse, Runx3 is expressed in specific cell 
types in the peripheral nervous system, haematopoietic cells as well as epithelial cells 
in gastrointestinal tract (Inoue et al., 2002; Levanon et al., 2002; Li et al., 2002; 
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Taniuchi et al., 2002). In line with this, Runx3-null mice displayed numerous 
anomalies including motor dis-coordination, reduction in peripheral cytotoxic T cells, 
and hyperplastic gastrointestinal epithelium (Inoue et al., 2002; Levanon et al., 2002; 
Li et al., 2002).  
In the nervous system, Runx3 controls the axonal projection of proprioceptive 
dorsal root ganglion neurons and thus, the ablation of Runx3 leads to severe ataxia in 
mice due to less neurite outgrowth (Inoue et al., 2002). In the hematopoietic system, 













 helper T cells, failed to 
proliferate and displayed defective cytotoxic activity, suggesting that Runx3 has 
critical function in lineage specification and homeostasis of CD8-lineage T 
lymohocytes (Collins et al., 2009; Taniuchi et al., 2002).  
 
1.2.4 RUNX3, a tumour suppressor for gastrointestinal cancers 
A role of RUNX3 in the gastrointestinal epithelium was first implicated by the 
pronounced hyperplastic gastric epithelia of the Runx3 knockout mice (Li et al., 
2002). Further analysis revealed that the fundic and pyloric region of the stomach 
displayed excessive proliferation. This was attributed to the suppression of apoptosis 
and reduced sensitivity to the growth inhibitory effect of transforming growth factor-
beta (TGF- (Ito, 2008; Li et al., 2002). The dysregulated proliferation and apoptosis 
experienced by gastric epithelial cells following the loss of Runx3 are consistent with 
its role as a tumour suppressor in this tissue type. However, the neonatal death of 
C57/BL6 Runx3
-/-
 mice has hampered detailed examination of the phenotype at the 
later stage of life. To overcome this problem, immortalised mouse gastric epithelial 
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embryos in a p53
-/-
 background (Li et al., 2002). Concordant with the tumour 









 counterparts formed tumours in immuno-compromised nude 
mice (Li et al., 2002).  
More recently, Runx3-null mice in Balb/c genetic background that survived up 
to one year were generated for the examination of preneoplastic lesions in adult mice 
(Ito et al., 2011). Analysis of these mice revealed a phenotype that is remarkably 
similar to spasmolytic polypeptide-expressing metaplasia (SPEM), a preneoplastic 
lesion found in human gastric cancer (Goldenring and Nomura, 2006; Ito et al., 2011). 
As Runx3 is prominently expressed in pepsinogen-positive chief cells and Muc5AC-
positive surface mucous cells, it may be involved in the differentiation of these 
lineages. Indeed, loss of chief cells and antralisation of the stomach were observed in 
adult Runx3
-/-
 mice (Ito et al., 2011). This was likely consequent to the blockage in 
chief cells differentiation or trans-differentiation of chief cells into SPEM cells (Ito et 
al., 2011). Remarkably, the induction of an intestinal phenotype characterised by the 
upregulation of intestinal markers, Cdx2 and Muc2, was observed in the gastric 
mucosa of Runx3
-/- 
adult mice (Ito et al., 2011). These mixed characteristics of gastric 
and intestinal phenotypes in Runx3
-/-
 gastric epithelium indicates the occurrence of 
intestinal metaplasia (IM) (Ito et al., 2011). The above evidence suggests that loss of 
Runx3 in the gastric epithelium disrupts the identity of the epithelial cells causing the 
differentiation pathways to be easily altered by extracellular morphogenetic cues. 
More importantly, SPEM observed in Runx3-null mice was readily transformed into 
gastric adenocarcinoma when induced with a carcinogen, N-methyl-N-nitrosurea 
(MNU), indicating that the loss of Runx3 induces a pre-malignant state in the stomach 
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(Ito et al., 2011). Moreover, genetic ablation of Runx3 induced hyperplasia of gastric 
epithelia in the absence of Helicobacter pylori (H. pylori) infection or inflammation 
indicating that this is an epithelial cell autonomous phenomenon (Ito et al., 2011; Ito, 
2008). 
 The tumour suppressive function of Runx3 in mice is firmly supported by 
human clinical data. In human, loss of RUNX3 expression is strongly correlated to the 
genesis and progression of gastrointestinal cancer. Inactivation of RUNX3 was found 
in more than 80% of primary gastric tumours and gastric cancer cell lines due to 
hemizygous deletions, epigenetic silencing and protein mislocalisation (Ito et al., 
2005; Li et al., 2002). Furthermore, silencing of RUNX3 was prevalent in human 
colorectal carcinomas in which RUNX3 was inactivated in 40% of primary colorectal 
tumours and 60% of colorectal cancer cell lines (Ito et al., 2008). In addition, 
downregulation of RUNX3 is frequently observed in intestinal metaplasia (IM) which 
is often regarded as a precancerous state in gastric cancer (Li et al., 2002). Similarly, 
inactivation of RUNX3 induced intestinal adenomas in both human and mice, which 
provide favourable conditions for the progression of these adenomas to malignant 
adenocarcinomas (Ito et al., 2008). 
Chromosome 1p36, where RUNX3 resides, harbours a cluster of tumour 
suppressor genes, and is a deletion hotspot in diverse cancers of epithelial, 
hematopoietic, and neural origins (Bagchi and Mills, 2008). Examination of gastric 
cancer cell lines SNU1, NUGC3 and AGS together with clinical specimens revealed 
hemizygous deletions of RUNX3 occurred at frequencies which increase with tumour 
grade (Li et al., 2002). Moreover, epigenetic silencing of RUNX3 by promoter 
hypermethylation was found to be the most common aberrant methylation events in 
gastric and colorectal cancers (Ahlquist et al., 2008; Li et al., 2002; Oshimo et al., 
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2004; Soong et al., 2009; Subramaniam et al., 2009). The CpG dinucleotide sequence 
in the RUNX3 exon 1 region were completely methylated in RUNX3-negative cell 
lines whereas those that expressed RUNX3 were entirely methylation free (Li et al., 
2002). Subsequently, this phenomenon is also observed in bladder, breast, lung, 
pancreatic, brain cancers and hepatocellular carcinoma (Jiang et al., 2008; Kim et al., 
2004; Kim et al., 2005; Lau et al., 2006; Mueller et al., 2007; Sato et al., 2006; Woolf 
et al., 2003).  
Cytoplasmic sequestration of nuclear factor RUNX3 was also found in 38% of 
gastric cancer cases and in multiple cancer cell lines (Ito et al., 2005; Ito, 2008). 
Remarkably, cytoplasmic retention of RUNX3 in SNU16 cells resulted in larger 
tumour formation in nude mice (Ito et al., 2005). Localisation of transcription factor 
to the cytoplasm is thought to keep them in an inactive state. Therefore, the 
observation in SNU16 cells highlights the importance of the transcriptional activity of 
RUNX3 for its tumour suppressive function. Lastly, although the mutation of RUNX3 
turned out to be rare, a mutation R122C bears an amino acid substitution of arginine 
to cysteine was isolated from a gastric cancer patient (Li et al., 2002). This R122C 
mutation occurs within the evolutionarily conserved Runt domain and is capable of 
abolishing the tumour suppressive effects of RUNX3 (Li et al., 2002). The relevance 
of this mutation is underscored by the discovery of a mutation (R169Q) at the 
equivalent position in RUNX2 from a patient with the skeletal disorder cleidocranial 
dysplasia. Taken together, the above evidence strongly suggests that RUNX3 is a 





1.3 Gastric carcinogenesis 
Gastric cancer is the fourth most prevalent malignancy accounting for 
approximately one million new cases annually in the world (Ferlay et al., 2010). The 
incidence of gastric cancer is particularly high in Asia (especially in Korea, Japan and 
China), Eastern Europe, and parts of Central and South America, and it is about twice 
as high among men than among women (Figure 1.1) (Garcia et al., 2011). Although 
the mortality rates have been substantially declining for several decades, the absolute 
number of new cases per year is increasing due to an aging population (Aaltonen et 





Figure 1.1. Global variation in age-standardised stomach cancer incidence rates. Worldwide 
incidences of stomach cancer per 100,000 males (all ages). The incidence of gastric cancer is 
particularly high in Asia, Eastern Europe, and parts of Central and South America (Adapted from 




More importantly, it remains the third leading cause of cancer death worldwide, 
exhibiting a persistently high mortality rate (9.7% of all cancer deaths per year) 
irrespective of gender or geographical region (Ferlay et al., 2010). The prognosis for 
stomach cancer is generally rather poor, with 5-year relative survival below 30% in 
most countries (Brenner et al., 2009). The exceedingly poor prognosis of gastric 
cancer is attributed to its typical late diagnosis, high recurrence rate post-surgical 
resection and limited range of treatment options (Carl-McGrath et al., 2007; 
Macdonald et al., 2001). Therefore, understanding the pathogenesis of gastric cancer 
at the molecular level is of great importance for providing better diagnosis of gastric 
cancer at early stages and wider range of therapeutic alternatives. 
 
1.3.1 Aetiology of gastric cancer 
Human gastric carcinogenesis is a multi-factorial and multi-step process. It 
involves a temporal sequence of chronic gastritis, atrophic gastritis, intestinal 
metaplasia, dysplasia, primary carcinoma, invasive carcinoma and metastatic tumour 
(Carl-McGrath et al., 2007; Correa, 1992; Yasui et al., 2005). This precancerous 
cascade reflects the accumulation of genetic and epigenetic alterations that acquire the 
cells with hallmark capabilities of cancer. Based on Laurén classification, 
histologically, gastric adenocarcinoma is generally subdivided into two main 
categories: intestinal-type carcinomas and diffuse-type carcinomas (Lauren, 1965). 
For many decades, the aetiology of gastric cancer was totally obscure. Considerable 
efforts were made to explore and identify the complex aetiology of environmental and 
genetic risk factors which influence the initiation, promotion and progression of 
gastric cancer (Chan et al., 2001; Correa, 2002; Kelley and Duggan, 2003; Stadtlander 
and Waterbor, 1999). In the early days, dietary and lifestyles factors were thought to 
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be the two major risk factors for gastric cancer (Correa et al., 1975). Indeed, more 
recently, wide-ranging prospective study has confirmed that high intake of salted, 
smoked and nitrated foods and low intake of fresh fruits and vegetables increase the 
risk of developing stomach cancer (Gonzalez, 2006; Howson et al., 1986; Kramer and 
Johnson, 1995; Odenbreit et al., 2000). Such diet causes stomach irritation by 
damaging the mucosa and disturbing the homeostatic balance between the gut flora 
and the epithelium, leading to atrophic gastritis. Injuries in the stomach epithelium 
cause excessive cell replication and increase the mutagenicity of carcinogens, thereby 
leading to cancer (Stadtlander and Waterbor, 1999; Takahashi et al., 1994; Tatematsu 
et al., 1975). On the other hand, the contribution of lifestyle factors such as alcohol 
consumption and cigarette smoking to stomach cancer had been intensively studied 
but the results are inconclusive (Hansson et al., 1994; Kabat et al., 1993; Nomura et 
al., 1990; Vaughan et al., 1995).  
The landmark discovery of Helicobacter pylori (H. pylori) in 1983 and its 
causal role in gastritis and peptic ulcers effected a re-examination of this classical 
view of gastric carcinogenesis. H. pylori are spiral-shaped, microaerophilic, Gram-
negative bacteria that are able to survive in acidic environment and colonise human 
gastric epithelium. The gastroenterologist Barry Marshall and the pathologist Robin 
Warren, in the 1980’s, first postulated for the association between H. pylori infection 
and human gastritis and gastric cancer (Kidd and Modlin, 1998; Marshall et al., 1985; 
Marshall and Warren, 1984; Warren and Marshall, 1983). This strong association was 
subsequently demonstrated in numerous studies in which independent cohorts of 
gastric cancer patients were retrospectively examined (Ekstrom et al., 2001; Forman 
et al., 1991; Fox and Wang, 2001; Nomura et al., 1991; Parsonnet et al., 1991; 
Uemura et al., 2001). H. pylori induces pre-neoplastic lesions that are similar to 
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spasmolytic polypeptide-expressing metaplasia (SPEM) in the stomachs of human 
(Craanen et al., 1992; Rugge et al., 1996; Schmidt et al., 1999) and experimental 
animals (Hirayama et al., 1996; Honda et al., 1998; Sugiyama et al., 1998; Watanabe 
et al., 1998). The disappearance of the inflammatory reaction post-eradication of the 
bacteria in human using antibiotics further supports that H. pylori is a causative agent 
(Blaser, 1992). During the past 20 years of research, the initially tentative association 
between persistent H. pylori infection and the development of gastric cancer has been 
well established, prompting the International Agency for Research on Cancer to 
classify H. pylori as type I carcinogen (WHO, 1994).   
H. pylori infects more than half of the world’s population from infancy, 
making it one of the most successful human pathogens (Suerbaum and Michetti, 
2002). H. pylori infection is highly prevalence in Asia, Africa and South America 
(Figure 1.2) (Bauer and Meyer, 2011). More than 50% of new gastric cancer cases 
and a 2.7- to 12-fold increase in the risk of developing gastric cancer can be attributed 
to H. pylori infection (Cover and Blaser, 1995; O'Connor et al., 1996; Parkin, 2006). 
This includes both intestinal-type and diffuse-type gastric cancers (Forman et al., 
1991; Nomura et al., 1991; Parsonnet et al., 1991; Talley et al., 1991; Uemura et al., 
2001). Critically, the prevalence of H. pylori infection mirrors the gastric cancer 
incidence in Asia, implying a strong association between them in this region  (Figure 
1.2) (Bauer and Meyer, 2011). Among East Asian countries, the overall prevalence 
rate was 59.6% in South Korea, 58.07% in China, 54.5% in Taiwan and 39.3% in 
Japan (Fujisawa et al., 1999; Hoang et al., 2005; Teh et al., 1994; Wang and Wang, 
2003). Among Southeast Asian countries, the reported prevalence rate was 57% in 
Thailand, 35.9% in Malaysia and 31% in Singapore (Deankanob et al., 2006; Fock, 






Figure 1.2. Worldwide prevalence of H. pylori infection. Bacterial infection rates were presented 
in percentage (%). H. pylori infection is highly prevalence in Asia, Africa and South America. 
(Bauer and Meyer, 2011). 
 
Interestingly, there is considerable genetic heterogeneity among the strains of 
H. pylori circulating in different geographical regions. Studies show that certain 
genotypes are more prevalent in gastric cancer patients than in control population, and 
are therefore regarded to be of high virulence or oncogenic potential (Atherton et al., 
1995; Tomasini et al., 2003). One of these genetic factors is the “cag pathogenicity 
island” (cag-PAI), which is a 40 kilobase fragment of the H. pylori genome that 
encodes 31 genes. This fragment contains the coding sequences for the oncoprotein 
CagA and a type IV secretion system for the injection of CagA and other bacterial 
materials into gastric epithelial cells (Odenbreit et al., 2000). Translocation of CagA 
into host cells is well-known to cause dramatic morphological changes in the cells as 
reflected by strong actin polymerisation and cellular elongation, term the 
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‘hummingbird’ phenotype (Segal et al., 1999). The status of CagA as a marker of 
pathogenic disease resulted from the observation that patients infected with CagA-
positive strain of H. pylori showed higher incidences of both gastric inflammation and 
gastric adenocarcinoma compared to CagA-negative strains (Blaser et al., 1995a; 
Huang et al., 2003; Nomura et al., 2002; Queiroz et al., 1998; Wu et al., 2003). 
Another virulence factor carried by 50% of H. pylori strains is vacuolating toxin A 
(VacA) which is responsible for epithelial cell damage and is associated with gastric 
cancer development (de Figueiredo Soares et al., 1998; Peek and Blaser, 2002). Given 
the profound influences that H. pylori exerts on host cell biology, understanding the 
mechanisms of how it ‘hijacks’ the host cells is critical for gaining novel strategies for 
gastric cancer treatment.   
Besides bacterial infection, infection with human herpes virus 4, or Epstein-
Barr virus (EBV) was also detected in approximately 10% of gastric carcinoma cases 
throughout the world (Takada, 2000). It has been reported that the antibody titres 
against EBV were significantly higher in subjects who later developed EBV-
associated gastric cancer than those subsequently developed non-EBV-associated 
gastric cancer or control subjects (Levine et al., 1995).  EBV was found to be 
associated with both intestinal- and diffuse-type gastric cancers (Shibata and Weiss, 
1992), and appeared to be more prevalent in the male than in female (Tokunaga et al., 
1993). The mechanism of EBV-mediated gastric carcinogenesis remains largely 







1.3.2 Inflammation and gastric cancer 
Inflammation is part of the complex biological response of cells to harmful 
stimuli, such as pathogens, damaged cells, or irritants (Ferrero-Miliani et al., 2007).  It 
is a protective attempt by the organism to remove the injurious stimuli and to initiate 
the healing process. Inflammation can be classified into acute or chronic. Acute 
inflammation is the body’s defence system to eliminate assaulting agents and prevent 
the dissemination of these agents in the body. However, if the body fails to end the 
inflammatory cycle, it may disturb the homeostatic balance of the immune system and 
result in chronic inflammation that exacerbates the wounds. Continual repairing of the 
wounding tissue by enhancing cell proliferation in a microenvironment enriched with 
inflammatory cells, growth factors, activated stroma and mutagenic agents potentiates 
or promotes cancer formation (Coussens and Werb, 2002).  Indeed, the similarities 
between conditions conducive to healing wound and tumorigenesis have prompted 
some researchers to consider tumours as wounds that never heal (Dvorak, 1986).  
The link between inflammation and cancer was first proposed by Rudolph 
Virchow in 1863 when he observed leukocyte infiltration in neoplastic tissue. The 
original hypothesis has been revisited numerous times in the subsequent years and a 
formidable body of evidence has been generated that corroborate inflammation-
mediated oncogenesis (Coussens and Werb, 2002). As a result of these researches, the 
causal relationship between inflammation and cancer is now well-accepted and 
tumour-promoting inflammation has been listed as one of the emerging hallmarks of 
cancer (Hanahan and Weinberg, 2011). The intimate link between chronic 
inflammation and cancer is particularly notable in the gastrointestinal tract where 
microbial contacts are frequent. Classical examples include hepatocellular carcinoma, 
inflammatory bowel disease (IBD)-associated colorectal cancer and H. pylori-
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associated gastric cancer. The aetiological agents of inflammation can be either 
infective, such as bacteria or viruses; or non-infective, such as physical or chemical 
irritants from the environment and diet.  
In recent years, the long-suspected influence of genetic susceptibility has 
come to the forefront. Current understanding points to the role of gene 
polymorphisms as yet another major determinant of aetiological forces (Correa and 
Schneider, 2005). The most prominent host polymorphisms associated with an 
elevated risk for gastric cancer were found in the Interleukin-1 (IL1) gene clusters, 
including IL1B (Interleukin-1 beta gene) and IL1RN (IL1 receptor antagonist gene) 
(El-Omar et al., 2000; El-Omar et al., 2003; Machado et al., 2001). Such 
polymorphisms were shown to affect the production of the proinflammatory cytokine 
IL-1 in response to H. pylori infection (Hwang et al., 2002). Subsequent study in 
mice demonstrated that ectopic production of IL-1 in the stomach leads to gastric 
inflammation and cancer (Tu et al., 2008). In addition to IL1 gene cluster 
polymorphisms, pro-inflammatory genotypes of TNFA (tumour necrosis factor alpha 
gene) and IL10 (Interleukin-10 gene) have also been identified as risk factors for 
gastric cancer (El-Omar et al., 2003). Not surprising that carriage of multiple 
proinflammatory polymorphisms of IL1B, IL1RN, TNFA and IL10 conferred greater 
risk for the disease (El-Omar et al., 2003). More recently, genetic variations in the IL-
12 family of cytokines and receptors were also found to be associated with 
inflammatory disease in the gastrointestinal tract. In particular, the polymorphisms in 
the Interleukin-12 (IL-12) cytokine family genes including, IL12A and IL12B are 
associated with increased risk of gastric cancer in H. pylori infected individuals 
(Navaglia et al., 2005). Interestingly, similar associations have been observed for IL-
12 receptor family. For example, a non-synonymous short nucleotide polymorphism 
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(SNP) of IL23R (Interleukin-23 receptor gene) was found to be associated with 
elevated risk of gastric cancer (Chen et al., 2011; Chen et al., 2010).   
In general, the genes that encode cytokines involved in the regulation of 
inflammatory responses are genetically polymorphic and different genotypes may 
determine the disease outcome and response to drug treatment. These genetic 
variations add to the complex interplay between the host system and environmental 
risk factors, which together often lead to a state of chronic inflammation in the gastric 
mucosa (Carl-McGrath et al., 2007). The above clinic-pathological evidence points to 















1.4 RUNX proteins function as transcription factors 
RUNX proteins are context-dependent transcriptional regulators. Studies in 
Drosophila, mammalian and other systems revealed that RUNX proteins are able to 
either increase or actively inhibit gene expression by cooperating with different 
subsets of transcription factors or cofactors in specific cells or tissue types (Wheeler 
et al., 2002). The transcriptional role of RUNX factors are dictated by the Runt 
homology domain that confers sequence specific binding and interaction with their 
universal binding partner CBF (Ito, 2004; Kamachi et al., 1990). Although the Runt 
domain has intrinsic DNA-binding capabilities, its binding affinity increases markedly 
when complexed with CBF (Ogawa et al., 1993a; Ogawa et al., 1993b). The 
interaction between RUNX and CBF is sufficiently strong that they were originally 
co-purified as a heterodimer in H-ras transformed NIH 3T3 cells (Kamachi et al., 
1990). The consensus RUNX target DNA sequence was further defined by Kamachi 
and colleagues as PuACCPuCA, whereby ‘Pu’ denotes a purine base. Subsequently, 
the physical binding between Runt domain, CBF and DNA was also resolved using 
X-ray crystallography (Kamachi et al., 1990; Nagata et al., 1999; Tahirov et al., 
2001).  
 
1.4.1 Downstream targets of RUNX 
In many tissues, RUNX proteins act as transcriptional activators or repressors 
to regulate gene expression at both genetic and epigenetic levels. A classic example 
for synergistic regulation is the cooperative DNA-binding and transcriptional 
activation of T cell receptor and Moloney murine leukemia virus enhancer elements 
by RUNX1 and Est-1 (Kim et al., 1999; Sun et al., 1995; Wotton et al., 1994). In 
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addition, RUNX1 also cooperates with Myb, PU.1, and C/EBP transcription factors 
to transactivate various promoters and enhancers of the hematopoietic-related genes 
(Britos-Bray and Friedman, 1997; Hernandez-Munain and Krangel, 1994; Petrovick 
et al., 1998; Zaiman and Lenz, 1996; Zhang et al., 1996). On the other hand, RUNX 
proteins recruit co-repressors such as Sin3A or TLE/Groucho to bring about 
transcriptional repression of hematopoietic- and osteoblastic-related genes (Imai et al., 
1998; Javed et al., 2005; Levanon et al., 1998; Wang et al., 1998). Furthermore, 
RUNX proteins are able to control gene expression through remodelling the 
chromatin structure. At the epigenetic level, RUNX1 interacts with p300/CREB-
binding proteins to recruit histone acetyltransferase, p300/CBP-associating factor, 
resulting in the de-repression of myeloperoxidase gene during myeloid differentiation 
(Kitabayashi et al., 1998). In a different context, Runx2 interacts with switch/sucrose 
nonfermentable (SWI/SNF) protein complex and C/EBPβ to epigenetically de-repress 
osteocalcin gene during osteoblast differentiation (Villagra et al., 2006). More 
recently, RUNX proteins are found to localise in nucleolar organizing regions where 
they epigenetically silence the expression of ribosomal RNA (rRNA) genes during 
interphase and mitosis (Pande et al., 2009; Young et al., 2007a). 
RUNX family members play divergent roles in developmental processes and 
human diseases which are reflected in the distinct subsets of target genes regulated 
between each RUNX factors. For example, RUNX1 regulates a long list of genes that 
are involved in haematopoiesis, including CFS-1 receptor, PU.1, CCND3 and 
IGFBP-3 (Bernardin-Fried et al., 2004; Huang et al., 2008; Iwatsuki et al., 2005; 
Okada et al., 1998; Zhang et al., 1994). RUNX2 orchestrates bone and cartilage 
formation through its regulation of key osteogenic genes including osteocalcin, 
osteopontin, collagenase 3 and MMP9 (Ducy et al., 1999; Ducy et al., 1997; Jimenez 
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et al., 1999; Pratap et al., 2005). In comparison, the target genes of RUNX3 are 
relatively less established due in part to its diverse functions in development in 
multiple tissue contexts. Candidate gene approach has often been applied to study 
target genes of RUNX3 within a specific cellular context. For example, CD4 and 
TrkB regulation by RUNX3 were studied in thymocytes and neuronal cells 
respectively (Inoue et al., 2007; Taniuchi et al., 2002). As Runx3-null mice display a 
hyperplastic gastric epithelium with reduced apoptosis, the growth regulator p21 and 
proapoptotic gene BIM1 were studied and established as RUNX3’s target genes in 
gastric epithelial cells (Chi et al., 2005; Yano et al., 2006). More recently, Claudin-1 
and AKT1 were also identified as target genes of RUNX3 in human gastric cancer 
cells (Chang et al., 2010; Lin et al., 2012). Despite these advances, much remains 
unknown of the full function of RUNX3 that could explain its frequent silencing in 
human gastric cancers.  
 
1.4.2 Identification of IL23A as a novel target gene of RUNX3 
As a first step to elucidate the genetic programme maintained by RUNX3 in 
gastric epithelial cells, an expression microarray study was previously performed 
(unpublished data). In this study, exogenous RUNX3 was reintroduced into a RUNX3 
non-expressing gastric cancer cell line, AGS. Changes in global gene expression were 
monitored by the analysis of RUNX3- or control-transfected cells across five different 
time points. The relative expressions of significantly altered genes with a false 
discovery rate of less than 5% are presented in the form of an expression ‘heat map’ 
as shown in Figure 1.3. In this study, 151 genes were found to be differentially 
expressed in the presence of exogenous RUNX3, of which 70 and 81 genes were 
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Figure 1.3. Heat map representation of a subset of candidate RUNX3 target genes. Time points 
of experiment are presented from left to right. ‘C’ and ‘R3’ denote control- and RUNX3-transfected 
cells respectively. Red colour in the heat map represents overexpressed genes; green, 
underexpressed genes; black, genes showing similar expression levels in RUNX3- verses control-
transfected cells.  
 
To extract biological insights from these microarray data, Gene Set 
Enrichment Analyses (GSEA) were performed (Edelman et al., 2006; Subramanian et 
al., 2005). Among the gene sets which are significantly correlated to ectopic RUNX3 
expression in AGS cells include those involved in the Wnt and apoptotic pathways 
(Figure 1.4). This is consistent with previous reports of RUNX3’s ability to attenuate 
the Wnt pathway, and its role as a gastric tumour suppressor (Chi et al., 2005; Ito et 
al., 2008; Li et al., 2002; Yano et al., 2006). In addition, this analysis revealed a group 
of genes involved in the immune response which are downstream of Interferon, 
Interkeukin-4 and -6 (Figure 1.4).  This hints at a novel function of RUNX3 in the 
immune response of gastric epithelial cells. Among the top 15 high-confidence 
candidate target genes, IL23A emerged as a prime candidate as it was strongly 
upregulated by RUNX3 (Table 1.1). With the interest of understanding the immune-
related function of RUNX3 in gastric epithelial cells, IL23A was chosen for 
downstream validation. IL23A encodes a 19 kDa subunit (p19) of the 
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proinflammatory cytokine IL-23, which plays a crucial role in host immunity and 
exhibits the effector functions of a novel class of helper T cells, known as Th17 




Figure 1.4. Gene set enrichment analysis of the microarray data. Gene sets are grouped into 
biological pathways in which they are involved. A subset of gene sets that are correlated to the 




Table 1.1. Fifteen high-confidence candidate RUNX3 target genes from microarray. ‘’ indicates 




1.5 The biological functions of IL-23 
IL-23 is a heterodimeric inflammatory cytokine that belongs to the IL-12 
family that has been genetically linked to gastric cancer. IL-23 is composed of a 
unique IL23A (p19) subunit and a common IL12B (p40) subunit that is shared with 
IL-12 (Figure 1.5). This cytokine was first discovered in a structure-based 
bioinformatics search and appeared closely related in structure to the IL12A (p35) 
subunit of IL-12 (Oppmann et al., 2000). The sharing of subunits of the IL-12 family 
members is not limited to the ligands but also applied to their receptors. Both IL-23 
and IL-12 share a common receptor subunit IL12RB1 that dimerises with either 
IL23R or IL12RB2 for ligands binding and signaling (Langrish et al., 2004; Parham et 




Figure 1.5. Schematic diagram of IL-12 and IL-23: members of a small family of pro-inflammatory 
heterodimeric cytokines. Both cytokines share a common IL12B subunit that is covalently linked 
either to IL12A subunit to form IL-12 or to IL23A subunit to form IL-23 (Oppmann et al., 2000; 




Despite the common characteristics between IL-12 and IL-23, they play profoundly 
distinct roles in immunity. IL-12 is well-known for promoting the differentiation of 
type I helper T cells (TH1) from naïve T cells whereas IL-23 in concert with TGF- 
and IL-6 are critical for the expansion of TH17 cells (Aggarwal et al., 2003; 
Kobayashi et al., 1989; Langrish et al., 2005; Murphy and Reiner, 2002; Trinchieri et 
al., 1992). 
IL-23 plays a pivotal role in the coordination of organ-specific inflammatory 
responses. This was revealed in experimental autoimmune and inflammatory studies 
in mice. Mice that lacked the IL-23-specific component IL23A are resistant to T cell-
mediated diseases as summarised in Table 1.2. Cua et al. had demonstrated that IL-23 
but not IL-12 is essential for the development of central nervous system (CNS) 
autoimmune inflammation. This was supported by the evidence that intense 









 (lack IL-23) 
background (Cua et al., 2003). Subsequent studies by other research groups also 
suggest that mice that lack IL23a or IL23r were resistant to the development of 
autoimmune inflammation in the joint, gut, kidney and skin (Ghilardi et al., 2004; 
Hue et al., 2006; Langrish et al., 2004; Murphy et al., 2003; Uhlig et al., 2006; van der 
Fits et al., 2009). In contrast, widespread expression of IL23a in transgenic mouse 
model induced multi-organ inflammation, runting, infertility and premature death 
(Wiekowski et al., 2001). These pro-inflammatory activities of IL-23 have been partly 
attributed to its ability to support the development of auto-reactive TH17 cells which 
are characterized by the production of pro-inflammatory cytokine IL-17 (Bettelli et 
al., 2006; Langrish et al., 2005; Mangan et al., 2006; Veldhoen et al., 2006) . 
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Defect in DTH responses 
Resistant to developing EAE and CIA 
Resistant to bacterial and chemical 
induced IBD 
Cua et al., 2003;  
Langrish et al., 2005; Murphy et al., 2003; 
Ghilardi et al., 2004; Mangan et al., 2006; Uhlig 
et al., 2006; Hue et al., 2006; Cox et al., 2012 





  Resistant to T-cell mediated IBD Yen et al., 2006 
IL23r
-/-





 Susceptible to chemical induced colitis Cox et al., 2012 
(DTH: delayed type hypersensitivity; EAE: experimental allergic encephalomyelitis; CIA: collagen-induced arthritis; 
IBD: inflammatory bowel disease) 
Table 1.2. Summary of the knockout and transgenic mouse phenotypes associated with 
IL23a/IL23r signaling. 
 
A comprehensive sequence analysis revealed that IL23A may have gone 
through positive selection pressure that directs towards inter-population and intra-
species sequence conservations, supporting a critical physiological role for IL-23 
(Tindall and Hayes, 2010). Although the exact role of IL-23 to the host is obscure, 
promoting pathogenic autoreactive T cells could not be the primary function of a 
cytokine that is so conserved in many animals. Therefore, it is more likely that severe 
autoimmune pathologies associated with IL-23/TH17 pathway are a reflection of the 
breakdown of tolerance to “self” tissues and antigens due to their dysregulation 
(McKenzie et al., 2006). There is ever-growing evidence suggesting that IL-23’s 
primary function was most likely more primitive in origin and related to forming a 
robust innate immune response for first-line defence against environmental assaults, 
during infection in the peripheral tissues such as gut, skin and lung (Tato and Cua, 
2008). Indeed, further investigations had shed some light for the protective roles of 
this cytokine. Although the true role of IL-23 awaits to be found but the robust IL-23 




In the gastrointestinal tract, bacterial-dependent IL-23 expression has been 
reported in lamina propria dendritic cells of the terminal ileum (Becker et al., 2003). 
Although IL23a
-/-
 mice are resistant to the development of autoimmune diseases, 
these mice will eventually succumbed to infection due to impaired bacterial clearance 
(Happel et al., 2005; Huang et al., 2004; Mangan et al., 2006). It was known that 
TH17 is involved in the recruitment of neutrophils to the site of microbial infection 
(Cruz et al., 2006; Kolls and Linden, 2004; Meeks et al., 2009). Some infectious 
models with a defective IL-23/TH17 immunity were reported to have increased 
disease susceptibility due to reduced neutrophils response thus higher microbial 
burdens (Happel et al., 2005; Kelly et al., 2005; Khader et al., 2005; Meeks et al., 
2009). In the stomach, evidences are accumulating for the involvement of IL-23 in 
regulating TH17 cells, in H. pylori-infected gastric mucosa (Caruso et al., 2008). IL-
17, a key regulator of neutrophil chemotaxis, was produced in excess in stomachs 
infected with H. pylori (Luzza et al., 2000; Mizuno et al., 2005). These evidences 
support an important role of IL-23 in mucosal host defence and pathogen surveillance. 
It is when this response goes unchecked that the beneficial role of IL-23 gets 
overcome by its pro-inflammatory properties.  
While it is well recognised that the main source cells for IL-23 are activated 
antigen presenting cells (APC) include dendritic cells and macrophages, the 
possibility of additional cell types that secrete this cytokine has not been ruled out 
(Oppmann et al., 2000). In fact, more recent study does provide evidence that 
keratinocytes secrete IL-23 especially in Psoriatic skin (Piskin et al., 2006). Given the 
important role of IL-23 in pathogen surveillance, it is possible that RUNX3 regulates 
IL23A in the gastric epithelial cells as part of its role as a gastric tumour suppressor to 
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enable effective surveillance against pathogens as well as neoplasia. Understanding of 





1.6 Project aims and objectives 
 
1. To demonstrate the transcriptional regulation of IL23A by RUNX3. 
 
2. To investigate the upstream signals involved in the induction of IL23A. 
 
3. To demonstrate the functional effects of RUNX3-induced IL23A production in 




Chapter 2:  





2.1 Mammalian cell culture  
2.1.1 Cell culture condition  
Cancerous human gastric epithelial cell lines AGS, KATOIII, SNU1, SNU5, 
SNU16, SNU719, MKN1, MKN7, MKN28, MKN45, MKN74 and non-cancerous 
human gastric epithelial cell lines HFE-145, GES-1 were maintained in Roswell Park 
Memorial Institute (RPMI) 1640 medium (Invitrogen, CA, USA). The same medium 
was used for culturing the human acute monocytic leukaemia cell line THP-1. 
Monkey kidney fibroblasts COS-7 and human embryonic kidney cells HEK293T 
were cultured in 1000mg/L glucose and 4500mg/L glucose Dulbecco’s Modified 
Eagle Medium (DMEM) (Invitrogen) respectively. All media were supplemented with 
10% fetal bovine serum (FBS) (Thermo Scientific Hyclone, Logan, UT), 100U/ml 
penicillin, 100µg/ml streptomycin antibiotics (Invitrogen) and 2mM L-Glutamine 
(Invitrogen). Adherent cells were sub-cultured in 10-cm tissue culture dishes and 
suspension cells were sub-cultured in non-treated tissue culture flasks (Nunc A/S, 
Roskilde, Denmark). Cell lines were maintained at 37
o
C in a humidified atmosphere 
containing 5% CO2 in the Water-Jacketed CO2 Incubator (Forma Scientific, OH, 
USA). All cell lines were stored in multiple aliquots of recovery cell culture freezing 
medium (Gibco, CA, USA) in liquid nitrogen and passaged for fewer than three 
months after resuscitation.  
 
2.1.2 Ligands/agonists and inhibitors treatments 
To activate the Toll-like receptors (TLR) and NOD-like receptor (NLR) 
pathways, cells were treated with 1µg/ml LPS, 1µg/ml Zymosan, 1µg/ml Pam3CSK4, 
1µg/ml Poly I:C, 1µg/ml R-848, 100µg/ml Flagellin, 10g/ml NOD1 (C12-iE-DAP) 
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or 50g/ml NOD2 (N-glycolyl-MDP) agonists (gifts from Dr. Vinay Tergaonkar, 
IMCB, A*STAR). In addition, 10ng/ml of human recombinant TNF-, IL-1, IL-1, 
IL-6, IFN- and/or 5ng/ml of TGF- (Peprotech, NJ, USA) were used to activate 
immune pathways in gastric epithelial cell lines. Cells were treated with the ligands 
for the indicated periods prior to quantitative RT-PCR (qRT-PCR) or Western-blot 
analysis. To block SHP2/Erk signaling pathway, cells were pre-treated with 50M of 
SHP2 protein tyrosine phosphatase (PTP) inhibitor, NSC87877 (R&D Systems, 
Minneapolis, MN) for 3h prior infection with Helicobacter pylori. To inhibit protein 
secretion, cells were treated with 1X Brefeldin A solution (eBioscience, CA, USA) 8h 
prior harvesting for Western blot analysis.  
 
2.1.3 DNA plasmids transfection and dual-luciferase reporter assay 
For the introduction of exogenous DNA plasmids into the cells, cells were 
transfected at 60-80% confluency. AGS and KATOIII cells were transfected using 
Lipofectamine
 
2000 reagent (Invitrogen) in 24-well tissue culture plates. IL23A 
promoter firefly reporter vector (1 – 2g), promoter-less Renilla luciferase reporter 
vector pRL-empty (250 – 500ng) and various expression vectors or empty vector (1.5 
– 2g) were co-transfected into the cells for 24 – 48h. Expression vectors used 
include pcDNA-FLAG encoding a FLAG-epitope as mock control, and pcDNA-
RUNX3 encoding amino-terminal FLAG-tagged human RUNX3 (Bae et al., 1995). 
Dual-Luciferase Reporter Assay System (Promega, Madision, USA) was used 
to measure the Firefly and Renilla luciferase activities of transfected cells according 
to the manufacturer’s protocol. Briefly, media were removed and 100l of 1x Passive 
Lysis Buffer (PLB) (Promega) was dispensed into each well. The cells were then 
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subjected to 2 cycles of freeze-thaw to ensure efficient lysis. Subsequently 40l of 
cell lysate was loaded on a 96-well assay plate (Nunc A/S), mixed with equal volume 
of Luciferase Assay Reagent II (LAR II) to quantify firefly luminescence using 
Veritas Microplate Luminometer (Turner Biosystems, CA, USA).  Renilla 
luminescence was measured by the addition of 40l Stop & Glo Reagent.   
 
2.1.4 Transient transfection of small interfering RNA (siRNA) 
For the introduction of siRNAs into cells, cells were seeded in antibiotics-free 
media one day before transfection in 24-well or 6-well tissue culture plates. The 
confluency of the cells during transfection is approximately 50%. Between 5 and 15 
pmol of ON-TARGETplus SMARTpool scrambled (control), RUNX3 and/or RUNX1 
siRNAs (Thermo Fisher Scientific, MA, USA) were transiently transfected into HFE-
145 cells using jetPRIME transfection reagent (Polyplus-transfection SA, Illkirch, 
France) for 48h followed by TNF- (10ng/ml) treatment and H. pylori (MOI100) 




















2.2 Helicobacter pylori culture and infection of mammalian cell lines 
 Helicobacter pylori (H. pylori) wild-type strain (NCTC11637) and its CagA-
defective isogenic strain (CagA) are kind gifts from Dr. Masanori Hatakeyama 
(Hokkaido University, Japan).  Both strains of bacteria were streaked and cultivated 
on a Trypticase Soy Agar supplemented with 5% sheep blood (Biomed Diagnostic, 
USA) to form colonies. H. pylori was cultivated at 37°C in a humidified and micro-
aerophilic atmosphere with 6–12% O2 and 58% CO2 generated using Anaero Pack-
MicroAero (MGC, Tokyo, Japan) in a sealed container for 3 days. Prior infection of 
mammalian cells, broth culture was prepared by inoculating colonies of H. pylori 
from agar into Brucella broth (Sigma-Aldrich, St. Louis, USA) supplemented with 
10% FBS and grown under the same atmosphere for 24h. Gastric cancer cell lines 
were seeded in a 6-well or 12-well tissue culture plates and infected with H. pylori 















2.3 Lentivirus production and transduction 
 Lentiviruses were produced according to the protocol described by(Tiscornia 
et al., 2006)with minor modifications. Briefly, 0.7x10
6
 HEK293T cells were seeded 
on a 6-well plate pre-coated with 0.001% of poly L-lysine (Sigma-Aldrich) one day 
before transfection. Lenti-Control, -RUNX3 or -RUNX3
R178Q
 transfer vectors (1µg) 
were co-transfected into HEK293T cells along with third generation packaging 
plasmids containing pLP/VSVG (1µg), pLP1 gag/pol (0.66µg) and pLP2 Rev 
(0.33µg) (ViraPower Lentiviral Expression system; Invitrogen) using 10µl of 
FuGENE HD (Roche, Basel, Switzerland). The cells were washed with PBS 18h post-
transfection and replaced with fresh DMEM supplemented with 15% FBS (Thermo 
Scientific HyClone). The virus-containing supernatants were harvested at 36h and 48h 
post-transfection. Viruses harvested at two different time points were pooled before 
freezing in aliquots at -80°C. For lentiviral transduction, cells cultured in 6-well or 
12-well plates at 80% confluency were incubated with 1/3 volume of virus-containing 
supernatants for 24h before splitting them for downstream experiments. Infected cells 
were subjected to TNF- treatment and/or H. pylori infection followed by qRT-PCR 
and/or western-blot analysis. For safety purposes, supernatants from infected cells 
were collected and filtered with 0.22m hydrophilic PVDF membrane filter unit 









2.4 Generation of wildtype and mutant IL23A promoter-reporter constructs 
2.4.1 Molecular cloning 
Human IL23A promoter sequence (Genebank accession no NM_001265) was 
obtained from UCSC Genome Bioinformatics (http://www.genome.ucsc.edu/). The 
-1200 to +105 of human IL23A promoter was reversed transcribed into cDNA and 
amplified by polymerase chain reaction (PCR). PCR amplification was performed in a 
50μl reaction mixture containing 1.25U of Pfu Turbo DNA polymerase (Invitrogen), 
1X Pfu Turbo amplification buffer, 0.25 mM of dNTPs (Finzymes, Espoo, Finland), 
0.8M of forward primer (5’-GGACAAGTTTCTACGCGTAAAAGGGTCAAC-3’) and 
0.8M of reverse primer (5’-GAATCTCTGCCCAGATCTACTTGCTTTGAG-3’) using 
GeneAmp® PCR system 9700 (Applied Biosystems, CA, USA). The PCR cycling 
parameters consist of 24 cycles at 95
o
C for 30s, 55
o
C for 30s and 68
o
C for 20min. 
Final extension at 68
o
C for 20min was performed. PCR products were analysed by 
agarose gel electrophoresis and the band of correct size was excised and recovered 
with QIAquick gel extraction kit following manufacturer’s protocol (QIAGEN, 
Hilden, Germany). The PCR products were cloned immediately upstream of firefly 
luciferase gene via 5’ Mlu I and 3’ Bgl II sites in the pGL3-Basic plasmid, a firefly 
luciferase reporter vector (Promega, Madision, USA). The ligation of digested PCR 
products (3l) and linearised pGL3-Basic vector (3l) was performed using T4 DNA 
ligase (1l) (NEB, Ipswich, MA, USA) and incubated at room temperature for 1h or 
16°C overnight in a 10μl reaction. The cloning of the -1.2kb IL23A promoter was 





2.4.2 Site-directed mutagenesis 
 Mutant IL23A promoter constructs were generated using the QuikChange® II 
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Wild-type IL23A 
promoter (-1.2 kb) sequence was used as a template and the PCR reaction mixture 
was set up as described in section 2.4.1. Primers listed in Table 2.1 were used to 
mutate putative RUNX and NF-B binding sites in IL23A promoter, as well as to 
generate truncated versions of IL23A promoters by PCR amplification. Compound 
mutants were generated by mutating individual sites in series. The amplified PCR 
products were subjected to Dpn I (Biolabs, UK) restriction enzyme digestion at 37°C 
for 4 h to completely digest the methylated parental plasmid DNA and the enzyme 
was subsequently denatured at 72°C for 20 min. The Dpn I digestion was visualised 


























-300 to -600 
d2-R 5’-ATATTTAAATTAATC|GGGAAGCCAGTATGA-3’ 
d3-F 5’-TCCTGGGCTTCCTAG|AGTTCTCCAAGTTCC-3’ 
-600 to -900 
d3-R 5’-GGAACTTGGAGAACT|CTAGGAAGCCCAGGA-3’ 
d4-F 5’-CGAGCTCTTACGCGT|CCATGGGGTCCAAAG-3’ 























Table 2.1. List of primers used for mutation and truncation of IL23A promoter. Red coloured lines 













2.4.3 Chemical transformation of Escherichia coli 
Ligated plasmids or Dpn I digested products were transformed into 50μl of 
home-made chemically-competent Escherichia coli XL10-Gold strain originally 
obtained from Stratagene. The mixture was sat on ice for 30min prior heat-shock at 
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o
C for 80s. The mixture was immediately returned to ice for 5min and shook in 
250µl Luria-Bertani (LB) medium at 37
o
C for 1h. The transformation mixture was 
subsequently plated onto LB agar plates containing 100μg/ml of ampicillin (Sigma-
Aldrich) and incubated overnight at 37
o
C for selection of successfully transformed 
bacterial cells. For the screening of positive clones, colonies were picked from the 
plate and inoculate into 3ml of LB prior shaking at 37
o
C for 4 hrs. For the purpose of 
amplifying existing DNA plasmids, the transformed bacteria containing the 
corresponding plasmids were inoculated directly into conical flasks containing 50ml 
of LB with ampicillin and incubated overnight for 15h.  
 
2.4.4 Plasmid DNA extraction and purification 
Mature cultures of bacteria were harvested by centrifugation at 9000rpm for 
15min at 4°C. DNA purification was performed at small-scale of 1.5ml of starter 
cultures with QIAprep Spin Miniprep columns (QIAGEN) or large-scale of 50ml of 
overnight cultures with QIAfilter Plasmid Midi/Maxi kit (QIAGEN) according to 
manufacturer’s protocols. DNA was dissolved in 50 l of elution buffer (10mM Tris-
Cl, pH8.5) and quantified using NanoDrop 1000 Spectrophotometer (Thermo Fisher 





2.4.5 Sequencing of plasmid DNA 
Clones of recombinant plasmid DNA were fully sequenced using BigDye 
Terminator version 3.1 Cycle Sequencing kit (Applied Biosystems). Each sequencing 
reaction was made up of 300ng of plasmid DNA, 3.2pmol of the forward or reverse 
primer (Section 2.4.1), 8μl of Terminator Ready Reaction Mix, and H2O to a final 
volume of 20μl. PCR was carried out in 96-well GeneAmp PCR System 9700 
(Applied Biosystems). The PCR reaction involves an initial denaturation at 95
o
C for 
3min and 40 cycles at 95
o
C for 30s, 52.5
o
C for 10s and 60
o
C for 4min. Purification 
and subsequent sequencing of the PCR products were carried out by the Sequencing 
Facility residing in 1
st


















2.5 Methods for detecting protein-DNA interaction 
2.5.1 Electrophoretic Mobility Shift Assay (EMSA) 
COS-7 cells were transiently transfected with plasmids encoding Flag-
RUNX3, Flag-Empty or CBF using FuGENE 6 (Roche) for 24h. Nuclear extracts of 
transfected cells were prepared using NE-PER nuclear and cytoplasmic extraction kit 
(Thermo Scientific, MA, USA). The subsequent steps were performed using 
LightShift® Chemiluminescent EMSA kit (Thermo Scientific). The stated 
combination of nuclear extracts were incubated with 10M biotinylated probes 
containing putative RUNX binding sites (Table 2.2) and 1g PolydI:dC in 1X EMSA 
binding buffer (HEPES, pH 7.9) in a 20l reaction on ice for 30min. For super-shift 
assays, 0.1 g anti-FLAG or anti-RUNX3 (5G4) antibody was added in and incubated 
for another 30min at 4°C. At the end of incubation, loading dye was added to the 
samples prior electrophoresis in 6% glycerol tolerant polyarylamide gel under native 
conditions. Next, protein-oligonucleotide complexes were blotted onto Hybond-N+ 
Nylon membrane (GE Healthcare, UK) followed by UV cross-linking using UVC 500 
UV Crosslinker (GE Healthcare). The membrane was blocked by using blocking 
buffer containing HRP for 30min at RT and washed four times using washing buffer 
for 10min at RT with shaking. Next, the membrane was incubated in substrate 
equilibration buffer for 5min prior incubation with enhanced chemiluminescence 
(ECL) detection reagents (GE Healthcare). Chemiluminescent signals were captured 
on X-ray medical film (Fuji Photo Film, Tokyo, Japan) using SRX-101A Medical 
































Table 2.2. Lists of oligonucleotides designed for EMSA studies. Red coloured letters denote the 
mutations in the corresponding RUNX sites. 
 
2.5.2 Chromatin immunoprecipitation (ChIP) 
Experiment was performed using UpState ChIP Assay Kit (Merck Milipore, 
Cork, Ireland) following manufacture’s protocol. Briefly, THP-1 cells (1 x 107) were 
induced with 1g/ml of LPS for 24 h and treated with 1% formaldehyde. Cross-
linking reaction was quenched by glycine and cells were washed in 1X PBS 
containing 1X Complete protease inhibitor cocktail (Roche) and 10mM PMSF. Cells 
were lysed by ionic buffer supplemented with Complete protease inhibitors cocktail 
and PMSF on ice. The cell lysate was sonicated with 6 sets of 12s on ice using a 
sonicator (Thermo Fisher Scientific) set at 30% of maximum power, which routinely 
yields sheared DNA of approximately 500bp in length. Immunoprecipitation (IP) to 
enrich for RUNX3/DNA complexes was carried out by addition of 5g of anti-
RUNX3 (Active motif, Carlsbad, CA) or anti-CBF (kind gift from Dr. Ichiro 
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Taniuchi) antibodies into the lysate followed by incubation with the pre-cleared 
Protein G Agarose. Enriched protein/DNA complexes were eluted in NaHCO3 buffer 
with 20% SDS and reverse cross-linked in 5M NaCl at 65°C for 4-5h. DNA was 
purified using QIAGEN spin columns after RNase A (37°C, 30min) and Proteinase K 
(45°C, 1-2h) treatments. Quantitative RT-PCR was carried out using primer pairs that 
span across putative RUNX binding sites A, BC, D or BCD, and a region not 
containing putative RUNX binding site as a negative control. The primers used for 















2.6 Transcriptomic analysis 
2.6.1 Purification of RNA 
Cells were washed with phosphate-buffered saline (PBS) and resuspended in 
350µl of RLT lysis buffer containing 1% -mercaptoethanol. RNA extraction was 
performed using RNeasy Mini Kit and RNase-free DNase Set (QIAGEN) following 
manufacturer’s protocol. Briefly, cell lysates were homogenised by vortexing for 1 
minute, followed by addition of 70% ethanol and samples were transferred to RNeasy 
spin column. On-column digestion of genomic DNA was carried out using 80µl of 
RNase-free DNase I set (QIAGEN). The spin column was then washed with buffers 
RW1 and RPE, followed by a final spin to remove residual ethanol. RNA was 
subsequently eluted in 30-50µl of RNase-free water and quantified by NanoDrop 
1000 Spectrophotometer (Thermo Fisher Scientific).  
 
2.6.2 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
Complementary DNA (cDNA) was synthesized from 0.2-1.0µg of total RNA 
using Omniscript reverse transcription (RT) kit (QIAGEN) in a T3 Thermocycler 
(Biometra, DE UK). The reaction mixtures were incubated at 37
o
C for 70min and the 
Omniscript reverse transcriptase was inactivated at 95
o
C for 5min. Quantitative PCR 
was performed in 7500 Real-time PCR system using 1µl of cDNA and TaqMan 
Universal PCR Master Mix or Power SYBR Green Master Mix (Applied 
Biosystems). TaqMan gene expression probes for human IL23A/p19, IL12B/p40, 
RUNX3, RUNX1 and GAPDH (endogenous control) are Hs00900829_g1, 
Hs99999037_m1, Hs00231709_m1, Hs00231079_m1 and Hs99999905_m1 
respectively. The gene-specific oligonucleotide primers used for SYBR Green-based 
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measurements are listed in Table 2.4. For the analyses of TaqMan and SYBR Green 
RT-PCR results, the threshold cycle (CT) values of genes of interest were normalized 

















2.7 SDS polyacrylmide gel electrophoresis (PAGE) and Western blot 
Cells harvested from culture were washed with 1x PBS and spun down as cell 
pellets. Ionic buffer supplemented with 1x cOmplete protease inhibitor (Roche) and 
10mM PMSF was used to lyse the cells by resuspending the pellets. Passive lysis of 
cells was performed on ice for 15 mins followed by three cycles of freeze-thaw with 
vortex to completely lyse the cells. Samples were centrifuge at 10,000 rpm for 10mins 
at 4
o
C to collect the cell debris. Cell lysates were then transferred into fresh ependoff 
tubes and the amount of protein was quantified using Bradford Assay. Briefly, 2l of 
cell lysate was mixed with 1998l of 1X Bradford dye in cuvette and incubate at RT 
for 5min prior assaying at 595nm wavelength using GeneQuant 1300 
spectrophotometer (GE Healthcare). After quantification, amount of protein was 
normalized against the most diluted sample, and SDS-containing loading buffer was 
added before boiling for 5mins on heat block for protein denaturation. To cool down 
the samples after boiling, denatured protein lysates were centrifuged at 10,000 rpm for 
5min at RT. Using 10 – 15% PAGE gel, 50g of protein was loaded into each well 
and electrophoresed at 200V and 40mA (for one gel) for approximately 1h. Precision 
Plus Protein
TM
 standards (Biorad, CA, USA) was used as protein marker. Proteins 
were transferred onto a PVDF membrane (Biorad) at constant 100V for 1 h 45 min. 
After transfer, membrane was blocked using 5% skim milk in PBST (PBS + 0.1% 
Tween) (Fonterra, AU, New Zealand) for 30 min – 1h before overnight primary 
antibody incubation at 4
 o
C. Detection of IL23A protein was performed using anti-
IL23A antibody (eBioscience) at 250x dilution and RUNX3 protein was detected 
using anti-RUNX3 5G4 antibody at 1g/ml (kind gift from Kotaro Tada). For the 
detection of housekeeping protein, -tubulin specific antibody (Sigma-Aldrich) was 
used at 50000x dilution. Membranes were washed 3x with PBST buffer at RT 
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followed by incubation with HRP-conjugated anti-mouse secondary antibody (GE 
Healthcare) for 1h. After washing off excess secondary antibody, membranes were 
incubated with ECL reagent (GE Healthcare) for 5mins and chemiluminescent signals 
























2.8 Functional assays 
2.8.1 Harvesting mononuclear cells from human peripheral blood 
Human peripheral blood was purchased from NUH Blood Donation Centre 
and different types of blood cells were separated by gradient centrifugation. Briefly, 
25ml of blood was carefully layered on Ficoll-Paque PLUS with 1.077g/ml density 
(GE Healthcare). Blood cells were fractionated by centrifuging at 2400rpm for 30min 
with slow acceleration and deceleration. Human peripheral blood will be separated 
into various layers including plasma, mononuclear cells, granulocytes and red blood 
cells (RBC). After discarding the top-most layer of plasma, peripheral blood 
mononuclear cells (PBMC) were harvested using Pasteur pipette and transferred into 
a fresh tube. PBMCs were washed in 1X PBS containing 2mM EDTA, and 
centrifuged at 2100rpm for 10mins. RBCs were lysed by RBC lysis buffer prior 
centrifuging at 1500rpm for 5min. Supernatant was discarded and PBMCs were 
resuspended in RPMI supplemented with 10% FBS and penicillin/streptomycin. 
Subsequently, 0.1 – 0.2 x 106 PBMCs in 100l of fresh medium were seeded into a 
96-well round bottom plate and incubated with equal volume of culture media 
harvested from gastric epithelial cells together with anti-CD3 antibody (clone OKT3) 
at 1.1ng/ml (suboptimal dose). PBMC were then cultured for three or seven days 
before analysis by flow cytometery. 
 
2.8.2 Neutralisation of IL23A in culture supernatant 
For the neutralization of secreted IL23A protein, 6-well plates were coated 
with 2g/ml of functional grade anti-IL23A antibody (eBioscience) or anti-mouse 
IgG (Santa Cruz) overnight at 4°C. The coated wells were washed once by 1X PBS to 
50 
 
remove unbound antibodies. Culture supernatants harvested from gastric epithelial 
cells were incubated on the coated wells for 2h at 37°C. The above step was repeated 
for another time by transferring the treated supernatants onto a fresh coated well. 
Supernatants were then collected and stored at 4°C for downstream immunological 
assays. 
 
2.8.3 Cell proliferation assay 
This assay was performed using CellTrace carboxyfluorescein diacetate, 
succinimidyl ester (CFSE) cell proliferation kit (Invitrogen) following manufacturer’s 
protocol. PBMCs harvested from human peripheral blood were re-suspended in pre-
warmed PBS with 0.1% BSA at a final concentration of 1x10
8
 cells/ml. PBMCs were 
stained with 10M/ml of CFSE solution at 37°C for 10min. The reaction was 
quenched by adding five volumes of ice-cold culture media to the cells followed by 
5min incubation on ice. Cells were concentrated by centrifugation (1500rpm, 5min) 
and washed 3 times by re-suspending the pellet in fresh media. In vitro culture of the 
PBMCs was set up and PBMCs were harvested at indicated time points. Cells were 
analysed using flow cytometer LSRII Special Order (BD Biosciences, San Jose, CA) 
with 488nm excitation and emission filters appropriate for fluorescein. Flow 
cytometry data were analysed using FlowJo computer software (Tree Star, OR, USA). 
 
2.8.4 Enzyme-linked immunosorbent assay (ELISA) 
Culture media of cells induced by the stated stimulants were harvested and 
stored at -20°C before use. ELISA was performed using IL-23, IFN- and IL-17 
ELISA Ready-SET-Go kit (eBioscience) following manufacture’s protocol. Briefly, 
transparent 96-well UV microplate (Corning, NY, USA) was coated with capture 
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antibody at 250x dilution at 4°C overnight. Unbound antibodies were removed by five 
washes of 1x PBST (PBS + 0.05% Tween). The wells were then blocked with 200l 
1x assay diluent for 1h at RT. The wells were washed five times using 1x PBST prior 
incubating with 100 – 200l of stimulated culture media for 2h at RT. Fresh medium 
was used as a negative control. After incubation, supernatants were aspirated and 
wells were washed with 1x PBST followed by incubation with detection antibody at 
250x dilution for another hour at RT. After binding of detection antibody, wells were 
incubated with avidin-HRP at RT for 30 mins in dark. The wells were washed up to 
seven times with 1x PBST for 2min each. After adding 100l of Substrate Solution 
for 15min at RT, the reaction was quenched by adding 50l of Stop Solution (1M 
H2SO4) and absorbance was measured at 450nm wavelength using microplate reader 
(Tecan, Männedorf, Switzerland).  
 
2.9 Statistical analysis 
The data are presented as with SEM. When two data sets were compared, the 
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3.1.1 Transcription regulatory mechanisms 
Transcription initiation is a key node of eukaryotic gene expression. Research 
in unicellular and multicellular organisms has amply demonstrated the prominence of 
transcription factors in controlling development and homeostasis (Davidson, 2001). In 
mammalian system, gene regulation involves a complex interplay between activators, 
repressors, the general transcription machinery, and chromatin (Oelgeschlager et al., 
1996). This intricate task is controlled by multiple different transcription factors that 
bind to specific DNA sequences and modulate the activity of RNA polymerase. The 
cis-acting regulatory sequences upstream of a gene where transcription factors 
assemble is termed promoters and enhancers (Blackwood and Kadonaga, 1998). 
These regulatory regions are encompassed by chromatin in the cells where alteration 
or “remodelling” of which is required to permit the access of transcriptional 
regulators.  
Transcription factors are often grouped into families according to the sequence 
and structure of their DNA-binding domains. The RUNX family of transcription 
factors are one such example where the name originates from its DNA-binding 
domain termed the Runt domain (Kamachi et al., 1990). This domain defines the 
binding of RUNX to its unique cis-regulatory elements and therefore its contribution 
to differential gene regulation. Thus, in general, understanding how transcription 
factors distinguish and bind to specific sites is a crucial step for the investigation of 
gene expression. However, due to the limitations of current technology in performing 
a systematic mutational analysis of an endogenous gene in vivo, artificial assays are 
often employed.  
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The most widely-used functional assay for promoter analysis is genetic 
reporter assay (Brasier et al., 1989; Bronstein et al., 1996; de Wet et al., 1987; Wood, 
1995). Eukaryotic promoter sequences are typically ligated to a reporter gene that 
encodes an easily detectable enzyme, e.g. the firefly luciferase (luc), that acts as a 
surrogate reporter of transcriptional activity in the form of luminescent signal (Wood, 
1995). The expression of the reporter gene following its transfer into cultured cells 
provides a rapid and sensitive assay that quantifies the ability of the cloned promoter 
sequences to direct transcription. Through this approach, biologically active 
regulatory regions can thus be identified, and in vitro mutagenesis can be used to 
determine the roles of specific sequences within the cloned region.  
After defining the DNA sequence elements responsible for regulating a gene, 
one can further demonstrate the specific binding of the transcription factors to the 
functional sites. One biochemical approach to analyse protein-DNA interaction is to 
perform electrophoretic-mobility shift assay (EMSA) by using synthesised 
oligonucleotides comprising the functional binding sites (Fried and Crothers, 1981; 
Garner and Revzin, 1981). Binding of the protein-of-interest to DNA can be studied 
by the formation of retardation complexes during electrophoresis in a non-denaturing 
gel. To determine the specificity of the protein-DNA interaction for the transcription 
factor-of-interest, an antibody that is specific to the transcription factor can be added 
to create an even larger complex with a greater retardation or ‘shift’ in the 
electrophoresis. This method is referred to as a supershift assay, and is used to 
unambiguously define the presence of a specific protein-DNA complex.  
 The approaches described in the preceding paragraphs study are commonly 
employed to study the transcriptional regulation of genes on naked DNA. However, 
this is not the case for transcriptional regulation inside the cells where the DNA of all 
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eukaryotic cells is tightly bound to histones that constitute the chromatin. Thus, 
reporter gene assay needs to be complemented by studying the direct products of 
transcription, messenger RNA (mRNA), which are representative of endogenous 
promoter activity. In addition, EMSA experiments ought to be reinforced by 
accessing the in vivo promoter occupancy at the chromatin level in vivo. One of the 
frequently used assays for such purpose is chromatin immunoprecipitation (ChIP) 
(Bauer et al., 2002; Gilmour and Lis, 1985; Jackson, 1978; Solomon and Varshavsky, 
1985). This method ascertains the physical association of a known transcription factor 
with a specific genomic region in living cells. The protein-DNA interaction is often 
more complex at the genomic level as the binding of transcription factors on the 
regulatory sequences may be influenced by the presence of other transcription factors 
or co-factors. 
  
3.1.2 RUNX3: a transcription factor with tumour suppressor functions 
Cancer is caused by the accumulation of defects in many genes, especially 
those involved in important pathways, as a function of time, leading to an invasive 
malignancy. The hallmarks of cancer cells encompass a combination of dysregulated 
signaling pathways such as those involved in growth and death signals. Ultimately, 
transcription factors participate in all of these pathways by effecting the upregulation 
or downregulation of specific genes. Crucially, a lot of proto-oncogenes, oncogenes 
and tumour suppressor genes encode for transcription factors, for example p53, c-
Myc, ETS-1, STAT and AP-1. The RUNX family proteins, which were discovered as 
context-specific transcriptional regulators, possess tumour suppressive functions in 
multiple tissues. Among all three RUNX members, the biological roles of RUNX3 
appear to be the most diversified and complex. It is well-established that RUNX3 is 
56 
 
involved in neuronal development and immune cell functions, and acts as an 
important tumour suppressor in gastric epithelial cells (Section 1.2.3 and 1.2.4). 
Similar to other RUNX proteins, RUNX3 achieves its roles by specific 
interaction and partnership with other transcriptional regulators and signaling 
pathways. In the gastrointestinal epithelium, RUNX3 functions as an important 
regulatory node for both the tumour suppressive TGF- pathway and oncogenic Wnt 
signaling (Hanai et al., 1999; Ito et al., 2008; Ito and Miyazono, 2003). Being an 
integral component of the TGF- signaling pathway, RUNX3 cooperates with 
SMADs in gastric epithelial cells to activate the transcription of target genes such as  
p21
WAF/Cip1 
(Chi et al., 2005). On the other hand, RUNX3 acts as an attenuator of the 
canonical Wnt pathway through direct interaction with -catenin and TCF4 thereby 
down-regulating Wnt target genes c-Myc, cyclinD1, EphB2 and CD44 (Ito et al., 
2011; Ito et al., 2008). However, due to a restricted number of target genes identified 
to date, the full spectrum of RUNX3’s role as a tumour suppressor remains to be 
explored (section 1.4.1). 
Identification of target genes often expands the understanding of known 
biological roles of a transcription factor and may reveal unappreciated and unexpected 
functions. By employing the cDNA expression microarray technology (section 1.4.2), 
cytokine gene IL23A was identified as a high-confidence candidate target gene of 
RUNX3. This interesting observation points to a novel immune-related function of 
RUNX3 in gastric epithelial cells. To explore this possibility, experiments described 






3.2.1 Validation of the regulation of  IL23A by RUNX3 in gastric cancer cell lines 
IL23A was identified as a putative RUNX3 target gene in AGS cells using 
cDNA expression microarray technology (Section 1.4.2). To validate the above 
observation, RUNX3 was transiently and ectopically expressed in a panel of three 
RUNX3-negative gastric epithelial cell lines including KATOIII, MKN28 and 
MKN7. In addition, AGS cell line was included to act as a biological replicate of the 
microarray experiment. By semiquantitative and quantitative RT-PCR, the induction 
of IL23A expression by ectopic RUNX3 was observed in five out of six cell lines 
(Figure 3.1A and 3.1B). The conservation of this regulation in multiple gastric cancer 
cell lines of heterogenous origins provides compelling evidence that RUNX3 is 


















Figure 3.1. RUNX3 upregulates IL23A in multiple gastric cancer cell lines. Four RUNX3-null 
gastric epithelial cell lines were transiently transfected with RUNX3-expression vector for 24 and 
48 hours. IL23A transcripts were ascertained using (A) semiquantitative and (B) quantitative RT-
PCR. The qRT-PCR values of IL23A were normalised with those of GAPDH and expressed 
relative to the untransfected control ‘UT’. ‘UP’ denotes ‘unrelated protein’ and ‘R3’ denotes 










3.2.2 RUNX3 activates IL23A in a DNA-binding dependent manner 
To further investigate the positive regulation of IL23A by RUNX3, exogenous 
wildtype RUNX3-, RUNX3
R178Q
- and Control-expressing vectors were stably 
reintroduced into RUNX3-negative AGS cells by lentiviruses. RUNX3
R178Q
 bears an 
amino acid substitution of arginine to glutamine in the Runt domain of RUNX3 and is 
defective in DNA-binding (Inoue et al., 2007). Ectopic expression of wildtype 
RUNX3 (Lenti-RUNX3) in AGS cells led to a 20-fold increase in IL23A mRNA 
expression relative to the control-infected (Lenti-Control) sample (Figure 3.2). This 
marked increase was not observed for stable expression of RUNX3
R178Q
 (Lenti-
R178Q) in AGS cells, indicating that the induction of IL23A is dependent on 
RUNX3’s DNA-binding activity (Figure 3.2). As IL23A is a subunit of IL-23 belongs 
to the IL-12 family and closely resembles IL12A, the positive role of RUNX3 on all 
other IL-12 family members was examined. Surprisingly, the activating effect of 
RUNX3 was only observed for IL23A but no other family members of IL-12 
suggesting that RUNX3’s effect is unique to IL23A (Figure 3.3). 
 
 
Figure 3.2. RUNX3 activates IL23A transcript in a DNA binding-dependent manner. AGS cells 
were stably transduced with lentiviruses expressing either control (Lenti-Control), RUNX3 (Lenti-
RUNX3) or RUNX3
R178Q
 (Lenti-R178Q). Cells were harvested 48h post-infection and subjected to 
qRT-PCR. The values of IL23A transcripts were normalised with those of GAPDH and expressed 





Figure 3.3. The activating effect of RUNX3 is unique to IL23A. AGS cells were infected with the 
same series of lentiviruses described in Figure 3.2. Forty-eight hours post-transduction, cells were 
harvested for RNA extraction prior to cDNA synthesis. The expression of IL23A, IL27A, IL12A, 
IL12B and EBI3 transcripts were ascertained by qRT-PCR. The values were normalised with 
those of GAPDH and expressed relative to Lenti-Control calculated by Ct method. Data are 
presented as means ± SEM (n=3). (u.d.: undetectable) 
 
3.2.3 Putative RUNX binding sites in IL23A promoter 
Given the requirement of RUNX3’s DNA-binding ability for its activation of 
IL23A, the presence of RUNX3-responsive elements in the IL23A gene locus was 
determined. The promoter region of the IL23A gene from nucleotide (nt) -1250 to the 
transcriptional start site were first analysed using the computer programmes, TESS 
and TFSearch, against the online transcription factor consensus binding site database 
TRANSFAC (Heinemeyer et al., 1998). Among all the predicted transcription factor 
binding sites, four putative RUNX sites from nt-1161 to -1156 (site A), nt-171 to -166 
(site B), nt-163 to -158 (site C) and nt-115 to -110 (site D) were identified as shown in 
Figure 3.4A. These putative RUNX sites were further categorised as “regular” and 
“sub-optimal” to reflect their resemblance to the strict RUNX consensus binding 
sequence (Figure 3.4B). To demonstrate the functional relevance of these sites, the -
1200 to +105 upstream region of IL23A locus was cloned into a firefly luciferase 








Figure 3.4. Sequences of the human IL23A promoter and the cloned IL23A promoter region in 
the luciferase reporter construct. (A) Sequence of the IL23A promoter from the -1200 to +150 was 
shown. Four putative RUNX consensus sites, identified using TFSearch program (Heinemeyer et 
al., 1998), were boxed in the promoter region. A putative NF- site was highlighted in black; a 
TATA-like sequence was marked in red and a transcriptional start site was highlighted in yellow. 
(B) Schematic diagram of the IL23A promoter firefly luciferase reporter construct. The putative 
RUNX sites were classified into regular RUNX sites (A and C) and sub-optimal RUNX site (B and 
D). The RUNX sites were mutated individually and in series as depicted in the boxes. The red 




3.2.4 Mapping of RUNX3-responsive elements in the IL23A promoter 
Given the clear induction of IL23A by RUNX3 observed in the RUNX3-null 
gastric epithelial cell line, KATOIII (Figure 3.1), this cell line was chosen as a cell 
model to study the effect of RUNX3 on the cloned full-length (1.2kb) IL23A promoter 
in the luciferase reporter assay. Transient transfection of exogenous RUNX3 led to 
~6-fold increase in activity of the full-length IL23A promoter (Figure 3.5). This result 
suggests that functional RUNX binding site(s) are present within this cloned IL23A 
promoter. To identify the RUNX3-responsive elements in the IL23A promoter, a 
series of deletions were performed on the full-length IL23A promoter to generate 
truncated IL23A promoter fragments. The full-length promoter was divided into 
Regions 1, 2, 3 and 4 as depicted by the different colours in which Region 4 contained 
RUNX site A while the other three RUNX sites were located in Region 1 (Figure 3.5). 
The results showed that the deletion of Region 1 of the promoter completely 
abolished the induction of IL23A by RUNX3. Conversely, only subtle changes were 
observed when Regions 2, 3, or 4 were deleted despite the removal of RUNX site A 
(Figure 3.5). This observation indicates that site A is dispensable to RUNX3’s effect 
on IL23A promoter activity in in vitro reporter assays. The complete loss of RUNX3-
mediated induction following the deletion of the most proximal region (Region 1) 
clearly indicates that RUNX3 acts via the cis-acting elements within this promoter 









Figure 3.5. RUNX3 mediates its effect through Region 1 (-300 and -100) of IL23A promoter. A 
series of deletions of the -1200 to +105 IL23A promoter construct was created as depicted by the 
schematic diagrams on the left. The truncated promoters were transiently transfected into KATOIII 
cells together with either control or RUNX3 expression vector for 48 h. The firefly luciferase 
activities of the transfected constructs were then measured and normalised against the internally 
co-transfected Renilla luciferase reporter. Oval shape on the promoter indicates the RUNX 
binding sites and V shape on the promoter indicates deletion of the corresponding region. (d: 










3.2.5 Identification of functional RUNX binding sites 
To further pinpoint the RUNX sites responsible for transactivation of IL23A 
promoter activity by RUNX3, a series of point mutations were introduced into 
individual RUNX sites as depicted in Figure 3.4B. These mutations were generated 
initially into a reporter construct containing only the minimal region (Region 1) 
needed for RUNX3’s transactivating activity. Within the context of this minimal 
IL23A promoter, mutations of sites BC or site D led to a modest decrease in RUNX3-
responsiveness (Figure 3.6A). Complete abolishment of RUNX3’s activating effect 
was only observed in the triple RUNX sites mutant promoter. These results clearly 
suggest that all three RUNX sites were requisite for the activation of the minimal 
IL23A promoter by exogenous RUNX3 (Figure 3.6A). Lastly, the contribution of 
these three RUNX sites was studied in the context of the full-length IL23A promoter. 
Mutations of the three putative RUNX sites within Region 1 effectively abolished the 
~7-fold induction of the IL23A promoter activity by RUNX3, which was comparable 
to the truncated promoter activity bearing a deletion of the Region 1 (Figure 3.6B). 
These observations are consistent with the changes observed in the minimal IL23A 
promoter (Figure 3.6A and B). In summary, transactivation of the IL23A promoter by 
exogenous RUNX3 is mediated through sites B, C and D within the minimal promoter 











Figure 3.6. RUNX3 transactivates IL23A promoter through the three proximal RUNX binding 
sites. (A) IL23A minimal promoter constructs from which mutations of individual or multiple RUNX 
sites were generated as depicted in the schematic diagram on the left. These constructs were 
transfected into KATOIII cells together with either Control or RUNX3 expression vector. Cells 
were harvested 48h post-transfection for the measurment of the luciferase assay. (B) Compund 
RUNX sites mutants of full-length and minimal IL23A promoter constructs generated as shown in 
the diagram on the left. These constructs were transfected into KATOIII cells together with either 
Control or RUNX3 expression vector. The firefly luciferase activities of the transfected constructs 
were measured and normalised against the internally co-transfected Renilla luciferase reporter. 
The data presented are compilation of three independent experiments. On the promoter, oval 
shapes indicate the RUNX binding sites, V shape indicates deletion of the corresponding regions 
and X indicates mutation of the respective RUNX site. (d: deletion; m: mutation) (means ± SEM)  
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3.2.6 Involvement of RUNX1 in the regulation of the IL23A promoter 
Another RUNX family member that is expressed in normal gastric epithelium 
is RUNX1 (Sakakura et al., 2005; Usui et al., 2006). Similar to RUNX3, significant 
downregulation of RUNX1 was observed in gastric tumour tissues compared to the 
surrounding mucosa (Sakakura et al., 2005). As RUNX proteins share common DNA 
binding sequences, the potential role of RUNX1 in the regulation of IL23A was also 
examined. Similar to the exogenous RUNX3, ectopic expression of RUNX1 in both 
KATOIII and SNU16 cells led to an increase in the full-length IL23A promoter 
activity (Figure 3.7). Not surprisingly, RUNX1-mediated activation was ablated when 
the binding sites were disrupted (Figure 3.7). These results indicate that RUNX1 is a 
positive regulator of IL23A promoter in addition to RUNX3. Interestingly, the co-
expression of RUNX1 and RUNX3 led to an additive increase in the induction of 
IL23A promoter activity suggesting that RUNX3 and RUNX1 may play 
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Figure 3.7. Both RUNX1 and RUNX3 transactivate IL23A promoter in gastric epithelial cells. 
Gastric epithelial cell lines (A) KATOIII and (B) SNU16 were transiently transfected with Control, 
RUNX3 and/or RUNX1 expression vectors together with full-length IL23A reporter constructs for 
48h. Cells were harvested and the firefly luciferase activities of the transfected constructs were 
measured and normalised against the internally co-transfected Renilla luciferase reporter. 
 
3.2.7 RUNX3 physically interacts with IL23A promoter in vitro 
Having identified the three functional RUNX sites in IL23A promoter, the 
binding of RUNX3 on these sites in vitro were determined by electrophoretic mobility 
shift assays (EMSA). Biotinylated oligonucleotide probes containing consensus 
RUNX sites B and C (Probe_BC) and site D (Probe_D) were synthesised and 
incubated with nuclear extracts of COS-7 cells expressing either exogenous FLAG-
RUNX3 or unfused FLAG-tag as a control (i.e. Mock). The incubation of Probe_BC 
with nuclear extract from untransfected COS-7 cells resulted in the appearance of 
several retardation (EMSA) complexes (lane 2 in Figure 3.8A), suggesting that 
endogenous proteins present in COS-7 cells were capable of binding to this probe. As 
such, these bands were regarded as ‘non-specific’ bands, though the possibility that 
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they contained endogenous RUNX proteins cannot be ruled out. When Probe_BC was 
incubated with COS-7 nuclear extracts overexpressing exogenous RUNX3, additional 
retardation complexes were observed (lanes 2 and 3 in Figure 3.8A). This shows that 





Figure 3.8. The bindng of RUNX3 to RUNX sites B, C and D of the IL23A promoter determined 
by EMSA. (A) Biotinylated Probe_BC and (B) Probe_D were mixed with nuclear extracts of COS-
7 cells expressing exogenous FLAG-RUNX3 or FLAG-tag as a control (Mock). Supershift assays 
were performed by incubating the probes with nuclear extracts of COS-7 cells expressing FLAG-
RUNX3 in the presence of exogenous CBF, anti-RUNX3 (5G4) and anti-FLAG monoclonal 
antibodies. The above samples were resolved in a non-denaturing polyacrylamide gel for analysis 
of the presence of protein-DNA complexes. ( :RUNX3-specific complex;  non-specific complex) 
 
 
To verify the identity of the RUNX3-related EMSA complexes, super-shift 
assays were performed. The addition of COS-7 nuclear extracts containing the 
binding partner of RUNX proteins, CBF together with RUNX3, resulted in a further 
retardation (i.e. super-shift) of the RUNX3-related EMSA complexes (lanes 3 and 4 in 
Figure 3.8A). This is consistent with the formation of a larger protein-DNA complex 
containing the RUNX3/CBF heterodimer. To demonstrate the proteins that interact 
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with sites BC is RUNX3, a monoclonal antibody against RUNX3 (5G4) was used. 
This resulted in the super-shifting of all RUNX3-related bands due to the formation of 
larger EMSA complexes with the antibody (lane 5 in Figure 3.8A). Moreover, the 
addition of anti-FLAG antibody that recognised FLAG-RUNX3 resulted in a very 
similar pattern of super-shifts (lane 6 in Figure 3.8A), further confirming the RUNX3-
specific binding on sites B and C. Lastly, the ‘non-specific’ bands appeared to be 
affected by CBF and 5G4 antibody, suggesting a possible involvement of 
endogenous RUNX proteins.  
Similar results were observed when Probe_D was used in EMSA; RUNX3-
related complexes formed migrated up modestly with CBFand super-shifted in the 
presence of anti-FLAG antibody (Figure 3.8B). However, it was clear that RUNX3 
had a weaker binding affinity for Probe_D, as the intensity of the RUNX3-related 
bands was much lower relative to the non-specific complexes. This lower affinity of 
RUNX3 protein for Probe_D is consistent with the suboptimal nature of site D 
(Figure 3.4B). There is a possibility that additional transcription factors or cofactors 
are involved to enhance the binding of RUNX3 on this site. However, this event could 
not be recapitulated within a short and ‘naked’ EMSA probe (~20 nt).  
Together, the significant loss of RUNX3-responsiveness observed in 
luciferase reporter assays following the mutations of these sites is likely due to the 
ablation of direct RUNX3 binding on these sites as revealed by EMSA. To confirm 
these observations, interrogation of the binding of RUNX3 to the endogenous IL23A 





3.2.8 Establish a cell model for in vivo binding of RUNX3 on the IL23A locus 
To study the binding of endogenous RUNX3 on IL23A promoter in vivo, a cell 
model expressing both RUNX3 and IL23A proteins was first established. It has been 
reported that monocytes express IL23A and secrete the heterodimeric IL-23 
(IL23A/IL12B) in response to bacteria endotoxin lipopolysaccharide (LPS) (Carmody 
et al., 2007). Thus, two acute monocytic leukaemia cell lines KG-1 and THP-1 were 
tested with the same stimulant. Using a sandwich ELISA containing anti-IL23A-
specific capture antibody and anti-IL12B detection antibody, secretion of IL-23 was 
only detected in LPS-stimulated THP-1 cells but not in KG-1 cells (Figure 3.9A). 






Figure 3.9. The expression of endogenous RUNX3 and IL23A proteins in monocytic cell lines. (A) 
KG-1 and THP-1 cells were stimulated with 1g/ml of LPS for 6h. Supernatants collected from 
these cells were subjected to IL-23 ELISA for quantification of the secreted amount of IL-23. (B) 
THP-1 cells were cultured in the presence or absence of 1g/ml LPS for 6h. Whole cell lysates 
were then prepared and analysed for RUNX3, IL23A and -actin (loading control) protein 
expression using Western blot together with 5g of human recombinant IL-23 which acts as a 





Western blot analysis showed that RUNX3 was detected in resting THP-1 
cells and its expression was increased modestly upon treatment with LPS (Figure 
3.9B). In the case of IL23A, a ~19kDa band was detected in LPS-stimulated THP-1 
cells that corresponded well with the band of recombinant human IL-23 (rhIL-23) 
(Figure 3.9B). This is consistent with the results obtained from ELISA whereby the 
secretion of IL-23 was only observed in THP-1 cells treated with LPS. Although it 
appears that the latter method is more sensitive for the detection of IL23A. These 
results confirmed that THP-1 cells express endogenous RUNX3 and LPS-induced 
IL23A and is therefore a suitable cell model for studying in vivo binding of RUNX3 
on IL23A promoter. 
 
3.2.9 RUNX3 occupancy on IL23A promoter at the chromatin level 
After establishing THP-1 as a suitable cell model, chromatin 
immunoprecipation (ChIP) analysis was performed in the presence of LPS to 
determine the in vivo binding of RUNX3 on RUNX sites B, C and D in the IL23A 
promoter. Anti-RUNX3 and anti-CBF antibodies were used to pull-down RUNX3-
DNA complexes in formaldehyde cross-linked THP-1 cells. A schematic diagram that 
illustrates the target regions in IL23A promoter which were spanned by the 
corresponding primers was presented in Figure 3.10A. Using primers encompassing 
the various RUNX sites, the enrichment of genomic DNA fragments containing sites 
BC, D and BCD was observed (Figure 3.10B). Such enrichment was not observed in 
control samples that were incubated with anti-IgG antibody and no antibody, 
indicating that the enrichment is RUNX3-specific. In contrast, no precipitation was 
observed for the DNA fragment containing RUNX site A that was similar to the non-
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specific site control (Figure 3.10B). These results further support the earlier 
observation in reporter assay studies that site A is not involved in the regulation of 
IL23A by RUNX3 (Figure 3.5). Similar result was obtained when ChIP analysis was 
performed in AGS cells that had been transduced with Lenti-RUNX3 (Figure 3.10C). 
In this case, strong enrichments of genomic DNA fragments bearing Site B, C and D 
were observed for both polyclonal and monoclonal anti-RUNX3 antibodies. In 
summary, the data from EMSA and ChIP analyses demonstrate that the physical 
binding of RUNX3 to sites B, C and D of the proximal IL23A promoter is in 

























Figure 3.10. In vivo occupancy of RUNX3 on IL23A promoter in THP-1 and AGS cells. (A) 
Schematic diagram of IL23A gene locus and regions containing RUNX site or non-specific site 
spanned by corresponding set of primers (Table 2.3) (B) Chromatin immunoprecipitation (ChIP) 
was performed using THP-1 cells stimulated with LPS (1g/ml) for 24 hours. Anti-CBF and anti-
RUNX3 antibodies were used to immunoprecipitate DNA fragments that were cross-linked with 
RUNX3. Anti-IgG and no antibody were included as negative controls. PCR amplification of the 
DNA fragments were performed using primers designed to amplify the corresponding regions 
shown in (A) and quantitated using qRT-PCR method. The values were expressed relative to 
those of Region A in the presence of anti-IgG antibody.(C) The chromatin of AGS cells 
transduced with Lenti-RUNX3 virus was crosslinked and immunoprecipitated with rabbit IgG 
(rIgG) control, mouse IgG (mIgG) control, RUNX3 polyclonal, RUNX3 monoclonal (5G4 + 6E9) or 
H3K9Ace antibodies. The degrees of enrichment were measured using real-time PCR and 




3.2.10 LPS is not a potent inducer for IL-23 in gastric epithelial cells 
Gastric epithelial cells are not known to express IL23A or secrete IL-23. To 
demonstrate that the transcriptional regulation of IL23A by RUNX3 was translated 
into an increase in its protein expression, the level of IL23A was first assessed in the 
supernatants of gastric epithelial cell lines SNU16, MKN45, MKN1, KATOIII and 
AGS using IL-23 ELISA. As IL-23 was only detectable in THP-1 cells post-
stimulation with LPS (Figure 3.9), the same stimulant was applied to gastric epithelial 
cell lines. However, the secretion of IL-23 in gastric epithelial cell lines could not be 
readily detected even in the presence of LPS, in stark contrast to THP-1 cells (Figure 
3.11). Given the tight regulation of IL23A observed in THP-1 cells, it is possible that 
gastric epithelial cells are hyporesponsive to LPS and additional signals relevant to 




Figure 3.11. The secretion of IL-23 induced by LPS in gastric epithelial cell lines. A collection of 
five gastric epithelial cell lines and THP-1 cells were stimulated with 1mg/ml of LPS for 24h. 
Supernatants collected from these cells at the end of stimulation were subjected to sandwich 
ELISA for quantification of IL-23 secretion. The amount of cytokine was calculated based on the 






The importance of IL-23 has to date been focused on its involvement in 
immunity against pathogens and autoimmunity against ‘self’. The remarkable 
phenotypes observed in IL23A knockout and transgenic mouse models (section 1.5) 
had revealed that it is critically important for this cytokine gene to be maintained at a 
homeostatic level. As a first step towards understanding the link between RUNX3 and 
IL23A, the direct regulation of RUNX3 on IL23A is addressed in this chapter. 
IL23A was first identified from a microarray study of RUNX3 target genes 
using gastric cancer cell line, AGS as a cell model (section 1.4.2). In validation 
studies, IL23A was found to be frequently upregulated in multiple gastric cancer cell 
lines (Figure 3.1). The variation for the basal levels of IL23A transcript in different 
gastric cancer cell lines could reflect the different driver mutations each line has 
inherited from the different gastric carcinomas from which they were derived. It is 
well-known that cancer is a heterogeneous disease which is reflected by their 
phenotypic and genomic diversities (Marusyk et al., 2012). Tremendous amounts of 
studies have shown that cell lines derived from tumours not only recapitulate the 
phenotypes of primary tumours but their genetic landscape is remarkably similar to 
that of the primary tumours from which they originated (Lin et al., 2008; Neve et al., 
2006; Sharma et al., 2010; Sos et al., 2009). Therefore, the heterogeneity of cancer is 
preserved in cancer cell lines which serve as a useful tool for in vitro studies. Given 
the heterogeneity of gastric cancer cell lines, the remarkable conservation of 
RUNX3’s positive regulation on IL23A in multiple cell lines implicates that this may 
be of central importance to the basic functions of gastric epithelial cells (Figure 3.1).  
In line with the transcriptional function of RUNX3, the activation of IL23A 
was found to be dependent on its DNA binding ability (Figure 3.2). This is clearly 
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reflected in the lack of activation of IL23A by its DNA-binding defective mutant of 
RUNX3, RUNX3
R178Q
. The DNA-binding dependent transactivation of IL23A by 
RUNX3 supports a direct role of RUNX3 in the regulation of IL23A in human gastric 
cancer-derived cell lines. In addition, this positive role of RUNX3 is not observed in 
other close family members of IL-12 (Figure 3.3). This highlights the specificity and 
uniqueness of RUNX3’s effect on IL23A. Through a combination of promoter 
deletion and mutation analyses, RUNX sites B, C and D were shown to functionally 
contribute to the transactivation of IL23A promoter by RUNX3 (Figures 3.5 and 3.6). 
The presence of multiple functional RUNX sites in IL23A promoter implicates that 
RUNX3 is an important regulator of this gene. Interestingly, less than 50% decrease 
in RUNX3-responsiveness was observed for mutation of either sites B and C or site D 
in IL23A promoter (Figure 3.6A). The above observation implicates that these RUNX 
sites are interdependent for RUNX3’s function on IL23A. Such regulatory 
mechanisms revealed a tight regulation of IL23A by RUNX3 as mutations of all these 
sites are necessary to impair RUNX3’s activation. Furthermore, RUNX1 was found to 
be another positive regulator of IL23A promoter (Figure 3.7). The involvement of 
RUNX1 in this regulation through the same RUNX binding sites revealed a certain 
degree of overlapping functions for RUNX proteins in this regard. Such phenomenon 
is not uncommon and has been observed for other RUNX target genes such as IgC, 
Defensin-3 and MDR1 (Hanai et al., 1999; Javed et al., 2000; Westendorf et al., 
1998). Furthermore, the additive effects of RUNX3 and RUNX1 on IL23A promoter 
activity revealed that they play similar but not identical roles in this regulation. 
However, the consensus sequence is not the sole determining factor that directs 
RUNX binding, as the involvement of other transcription factors or co-factors in the 
cells will also influence their affinity to the binding site (Carey, 1998; Joshi et al., 
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2007; Mann et al., 2009; Merika and Thanos, 2001; Stein and Baldwin, 1993). As 
such, a detail study into the preference of RUNX3 and RUNX1 on the different 
functional binding sites in IL23A promoter may reveal more insights on the additive 
increase observed for IL23A promoter. 
 In EMSA analyses, the same proximal RUNX sites B-D were shown to be 
critical for the binding of RUNX3 on IL23A promoter. The appearance of RUNX3-
related EMSA complexes reflects the affinity of RUNX3 on sites B and C (Figure 
3.8A). Although the traditional view of specific DNA recognition is relied on static 
contacts with the bases but more recent discoveries reveal that it is a dynamic process 
influenced by the interaction with other proteins in the cells (Fuxreiter et al., 2011). 
The formation of multiple RUNX3-related EMSA complexes on sites B and C 
suggests that other transcription factors and co-factors in COS-7 nuclear extracts are 
involved in the binding (Figure 3.8A). Factors that have lower affinity may dissociate 
from the oligonucleotides during the process of electrophoresis leading to different 
retardation complexes. More importantly, all of these RUNX3-related EMSA 
complexes were super-shifted by RUNX binding partner, CBF and further shifted by 
antibodies that recognised RUNX3, thus clearly demonstrates the specificity of 
RUNX3 binding on sites B and C. In the case of RUNX site D, although EMSA 
analysis showed certain degree of specificity of RUNX3 binding, the affinity of 
RUNX3 on this site is low (Figure 3.8B). One possible explanation is the suboptimal 
RUNX consensus sequence for site D and additional transcription factors or co-
factors may be required to enhance RUNX3 binding.  
The induction of IL23A protein by LPS in THP-1 cells suggests that IL23A is 
a transcriptionally active locus that is accessible by transcription factors and co-
factors binding (Figure 3.9). Together with the increased expression of RUNX3 in this 
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cell line upon LPS treatment, THP-1 is a useful cell model to assess the association of 
RUNX3 with IL23A promoter in vivo. In ChIP assay, precipitation of genomic DNA 
fragments containing RUNX sites B, C and D by antibodies against RUNX3 and 
CBF confirmed the endogenous RUNX3’s binding on these sites (Figure 3.10B). 
ChIP measures the interaction of proteins with their target DNA sequences in living 
cells which is a dynamic process involving chromatin remodelling, as well as 
positioning and modification of nucleosomes (Pascual-Ahuir and Proft, 2012). Given 
the complexity of the above process, the clear enrichment observed for all three 
RUNX sites further supports the specificity of endogenous RUNX3 binding on IL23A 
at the chromatin level. 
Through a combination of quantitative real-time PCR, sequence analysis, 
reporter gene assays, EMSA and ChIP, this chapter uncovers the molecular 
mechanisms underlying the transcriptional regulation of IL23A by RUNX3. In THP-1 
cell model, the lack of IL23A expression in the absence of LPS suggesting that IL23A 
is specifically and stringently regulated by inflammatory stimulus.  However, unlike 
THP-1 cells, LPS is not a potent inducer for IL-23 in gastric epithelial cell lines 
(Figure 3.11). Given the significance of RUNX3 role in the regulation of this gene, 





Chapter 4:  
RUNX3 is a critical requirement for the 
induction of IL23A expression by inflammatory 





4.1.1 NF-B is a positive regulator of IL23A 
As with many cytokine genes, especially those involved in inflammatory 
responses, IL23A is a direct target gene of the NF-B (nuclear factor kB) pathway that 
plays a pivotal role in host immunity and inflammation. This was amply supported by 
data from mouse gene targeting experiments in which components of the NF-B 
pathway were targeted. NF-B-deficient monocytes isolated from c-rel-/- and relA-/- 
mice were defective in expressing IL23a in response to TLR (Toll-like receptor) 
ligands, indicating that NF-B is essential for the regulation of this gene (Carmody et 
al., 2007; Mise-Omata et al., 2007). This phenomenon was subsequently attributed to 
a proximal B binding site in murine IL23a promoter, which was requisite for 
induced IL23a expression (Mise-Omata et al., 2007). This regulatory mechanism 
appears to be conserved across species and NF-B induction of IL23A has been 
reported in human macrophages (Garrett et al., 2008). In the current study, this 
phenomenon is supported by the strong induction of IL23A in THP-1 cells by LPS, a 
potent activator of NF-B signaling (Figure 3.9). Given the constitutive expression of 
NF-B family members in a variety of cell types, it is likely that NF-B plays an 
important role in the regulation of IL23A in many tissue contexts, including the gastric 
epithelium. 
 
4.1.2 Activating the NF-B pathway in gastric epithelial cells 
In the stomach, a single layer of epithelial cells that separates the luminal 
contents of the mammalian stomach from the underlying tissues often represents the 
first line of defence of the body. Gastric epithelial cells, besides acting as a physical 
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barrier to protect the body from adverse environmental agents, have important 
immunological properties. The strategic location of gastrointestinal mucosal epithelial 
cells allows them to simultaneously interact with both luminal antigens and resident 
lamina propria immune cells which is important for mucosal immunity. A wide 
variety of stimuli, including pathogens, inflammatory cytokines, antigens and stress 
factors activate the canonical NF-B pathway in gastric epithelial cells (Pasparakis, 
2008).  
Gastrointestinal epithelial cells express a range of cytokine receptors that 
enable them activate the NF-B pathway in response to inflammatory signals, such as 
injury and infection of pathogens (Panja et al., 1998; Reinecker and Podolsky, 1995). 
This would trigger a cascade of cellular events that includes the secretion of 
chemokines for the recruitment of leukocytes; and cytokines for the amplification of 
the inflammatory signal and activation of host defence mechanisms (Burchett et al., 
1988; Elkon et al., 1997; Yamada et al., 2000). The most well-known inflammatory 
cytokines that activate NF-B signal transduction pathway in gastric epithelial cells 
are TNF- and IL-1(Pasparakis, 2008) Aberrant production of these cytokines were 
linked with gastric inflammation and cancer as discussed in section 1.2.6 (El-Omar et 
al., 2000; El-Omar et al., 2003; Oshima and Oshima, 2012). These highlight the 
importance of cytokine signaling pathways for the regulation of host immune 
response of epithelial cells in the stomach. 
In addition to the ability to response to cytokines, gastric epithelial cells are 
equipped with numerous germline-encoded pattern recognition receptors (PRR) to 
sense the presence of microbes via recognition of the conserved molecular structures 
known as pathogen-associated molecular patterns (PAMP). The best characterised 
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PRR are the Toll-like receptors (TLR) and NOD-like receptors (NLR), which play 
critical roles in distinguishing pathogens from commensal bacteria, and mounting a 
precise immune response (Kumar et al., 2009; Martinon et al., 2009; Wells et al., 
2011). TLR are localised on the cell membrane and/or endosomal membrane 
components to recognise extracellular and endocytosed PAMPs. In human, the 
majority of TLR identified to date have been shown to be present in the 
gastrointestinal epithelial transcriptome with the most well-studied being TLR4. 
However their spatial distribution in the epithelium, cell lineage specificity, and 
specific functions in different part of the gut remain unclear (Abreu, 2010; Ishihara et 
al., 2004; Schmausser et al., 2004; Schmausser et al., 2005; Wells et al., 2010). Unlike 
TLRs, which are membrane associated, NLRs are cyotosolic and responds to a wide 
range of bacterial ligands and toxins; as well as certain damage-associated molecular 
patterns (DAMP) of the host cell (Martinon et al., 2009; Williams et al., 2010). To 
date, the NLRs that have been well characterised in the gut are NOD1 and NOD2 
(NOD: nucleotide-binding oligomerisation domain protein) (Hirata et al., 2006; 
Hisamatsu et al., 2003; Kobayashi et al., 2005; Viala et al., 2004).  
At the onset of inflammation, this diverse range of stimuli that includes 
proinflammatory cytokines and bacterial components that triggers TLR and NOD 
signaling pathways, converge to activate IB kinase (IKK) complex (Abreu, 2010; 
Kim et al., 2008; Pasparakis, 2008). The activation of IKK complex will result in the 
phosphorylation and degradation of the inhibitory protein for NF-B (I-B) I-B, 
thereby releasing the NF-B into the nucleus and to activate the transcription of its 
target genes as depicted in Figure 4.1. (Abreu, 2010; Hayden and Ghosh, 2004; Kim 
et al., 2008; Verma et al., 1995; Wells et al., 2010). NF-kB is a heterodimeric 
transcription factors composed of various combinations of the Rel family of 
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transcription factors: c-Rel, RelA (p65), RelB, NF-B1 (p50/p105) and NF-B2 
(p52/p100). The most studied NF-B heterodimer is composed of p65 and p50. It is 
known that specific combination of these factors would confer variations such as 
induction kinetics, binding site and partner specificity that enables the fine-tuning of 




Figure 4.1. NF-B signal transduction pathway initiated by proinflammatory cytokines and 
pathogens in gastric epithelial cells. Proinflammatory cytokine such as TNF- and IL-1 as well as 
microbial components that bind TLR and NLR activate IKK (I-kB kinase). This activation event 
leads to phosphorylation and degradation of I-B (Inhibitory protein for NF-B) and translocation 






4.1.3 Signaling events triggered by H. pylori infection in gastric epithelial cells 
Helicobacter pylori (H. pylori), a human stomach pathogen that infects half of 
the world’s population is a major risk factor for gastric inflammation and 
malignancies (Peek and Crabtree, 2006). It is now recognised that H. pylori infection 
triggers majority of the inflammatory cascades that have been implicated in gastric 
pathologies. The association of H. pylori CagA-positive strains with higher grades of 
gastric inflammation and increased risk of gastric cancer highlights the role of CagA 
in H. pylori-mediated inflammatory response (Blaser et al., 1995b; Parsonnet et al., 
1997).  
During H. pylori infection, the CagA protein is injected into host gastric 
epithelial cells through a type IV secretion system, which is often followed by its 
phosphorylation by host Src kinase that enables CagA to target host proteins and alter 
cellular processes (Hatakeyama, 2008; Peek, 2005). An important interaction appears 
to be that between phosphorylated CagA and a host phosphatase known as Src 
homology domain-containing protein tyrosine phosphatase (SHP2), which promotes 
the activation of extracellular signal regulated kinase (ERK) signaling pathway, 
leading to the aberrant proliferation of infected cells (Asahi et al., 2000; Hatakeyama, 
2004; Higashi et al., 2002; Stein et al., 2000). The phosphorylation of CagA appears 
to be a key regulatory node for the action of this protein, as hypophosphorylated 
CagA is shown to interact with the Interleukin 6/11 receptor gp130 to transactivate 
the JAK/STAT pathway (Lee et al., 2010).  
In addition to CagA, the type IV secretion system also delivers H. pylori-
derived peptidoglycan (ie. iE-DAP) into host cells. This leads to the stimulation of 
intracellular NOD1, as it recognises H. pylori-derived iE-DAP, resulting in the 
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activation of NF-B (Viala et al., 2004; Watanabe et al., 2010). It has been reported 
that H. pylori-mediated activation of NOD1 results in robust production of 
bactericidal -defensin and pro-inflammatory cytokines from gastric epithelial cells 
(Hishida et al., 2010). It is held that these early responses are crucial for effective host 
defence and bacterial clearance (Viala et al., 2004; Watanabe et al., 2010). The 
signaling pathways activated in gastric epithelial cells during H. pylori infection is 
depicted in Figure 4.2. Given the prominent involvement of the NF-B pathway 
activated by pathogens or host cell factors in gastric epithelial cells, the emphasis of 





Figure 4.2. Alteration of gastric epithelial cellular signaling by H. pylori. H. pylori delivers 
peptidoglycan (PGN) and CagA into gastric epithelial cells via Type IV secretion system. 
Peptidoglycan enters into the host cells binds onto NOD1 for activation of NF-B. The injected 
CagA is phosphorylated by Src kinase that leads to activation of SHP2/ERK signaling whereas 
the hypophosphorylated CagA activates JAK/STAT signaling pathway. (gp130: IL-6 receptor; 
IKKs: Inhibitory B kinase complex; JAK/STAT: Janus kinase/signal transducer and activator of 




4.2.1 The induction of IL23A by inflammatory cytokines 
To determine if IL23A is regulated by the NF-B pathway in gastric epithelial 
cells, the gastric carcinoma cell line AGS was subjected to treatment with several NF-
B activating cytokines as well as other cytokines that are relevant to the regulation of 
this gene. Quantitative PCR analyses revealed that NF-B-activating cytokines TNF-
, IL-1 and IL-1 induced a 20-fold, 5.5-fold and 6-fold increase in IL23A 
transcripts relative to the unstimulated control (Mock), respectively (Figure 4.3). In 
contrast, no appreciable induction of IL23A was observed upon treatment with IFN- 
and IL-6, while TGF- had only marginal effects (Figure 4.3). In addition, a potential 




Figure 4.3. The effects of various inflammatory cytokines on the expression of IL23A. AGS is 
singly treated with 10ng/ml of human recombinant IFN-, IL-1, IL-1, IL-6 and TGF-(5ng/ml), 
and co-treated with 10ng/ml of TNF- for 6h prior to the quantification of IL23A mRNA using qRT-
PCR. The values were normalised with those of GAPDH and were expressed relative to the Mock 
control. Data are presented as means ± SEM. Data presented are a compilation of three separate 




However, no significant cooperation in IL23A induction was observed when AGS 
cells were co-treated with TNF- and various cytokines. Interestingly, the lack of 
additive effect also applied to IL-1 and IL-1, which resulted in significant 
activation of IL23A on their own (Figure 4.3). This observation suggests that TNF- 
and IL-1 are acting on a common pathway, most likely through the activation of NF-
B, with TNF- being the more potent activator. The lack of significant induction of 
IL23A by the other cytokines indicates that the TNF- signaling axis is the primary 
activator for this gene in AGS gastric epithelial cells. 
 
4.2.2 RUNX3 and TNF- cooperatively activates IL23A 
To investigate a potential involvement of RUNX3 in TNF--mediated 
induction of IL23A, AGS cells were transduced with lentiviruses to stably express 
wildtype RUNX3 (Lenti-RUNX3), RUNX3
R178Q
 (Lenti-R178Q) or no cDNA (Lenti-
Control) before treatment with TNF-. The results showed that TNF- treatment on 
Lenti-Control or -R178Q infected AGS cells resulted in ~20-fold induction of IL23A 
mRNA levels similar to the previous observations (Figure 4.3 and Figure 4.4). This 
induction was markedly augmented to 100-fold relative to that of Lenti-Control 
unstimulate levels in cells expressing wild type RUNX3 (Figure 4.4A). Importantly, 
this synergistic cooperation was consistently observed at the level of IL23A protein 
expression, whereby the highest level of IL23A protein expression was detected in 











Figure 4.4. The expression of IL23A in the presence of RUNX3 and TNF-. (A) AGS cells were 
transduced with Lenti-Control, -RUNX3 or -RUNX3
R178Q
 for 48h preceding treatment with 10ng/ml 
of TNF- for 6h. Transcript expression of IL23A was determined by qRT-PCR and the values 
were normalised against those of GAPDH and were expressed relative to the Lenti-Control 
(Mock) sample. The data presented are a compilation of three independent experiments (means ± 
SEM). (B) AGS cells transduced with the same series of lentiviruses were cultured with 10ng/ml 
of TNF- for 18h. Whole cell lysates were then prepared and analysed for IL23A, RUNX3 and -
tubulin (loading control) protein expression using Western blot. 
 
The induction of IL23A transcript and protein by TNF- and the cooperative 
effects observed for TNF- and RUNX3 were recapitulated in the established 
promoter reporter system (Figure 4.5A). The necessity of RUNX3 was demonstrated 
by the abolishment of cooperativity on the full-length IL23A promoter when the 
proximal RUNX sites (B, C and D) were mutated (Figure 4.5A). Furthermore, these 
observations could be reproduced in another RUNX3-negative gastric carcinoma cell 
line, KATOIII (Figure 4.5B). These data collectively indicate a functional 
cooperativition between RUNX3 and TNF-/NF-B, which was dependent on the 
proximal RUNX sites within the full-length IL23A promoter. It is important to note 
that the mutation of RUNX sites had no impact on the activation of IL23A promoter 
by TNF- per se, indicating that TNF- acts via a distinct cis-acting element (Figure 
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Figure 4.5. Changes in IL23A promoter activity in response to RUNX3 and TNF-. Left panel 
depicts the schematic diagrams of wiltype and mutant IL23A promoter luciferase reporter 
constructs. Oval shapes on the promoter indicate the RUNX binding sites and X indicates 
mutation of the corresponding RUNX site. These promoter reporter constructs were transiently 
transfected into the cells together with either control- or RUNX3-expression vector for 24h 
followed by TNF- (10ng/ml) treatment for 24h. The luciferase activities of the constructs were 
then measured and normalised against those of Renilla luciferase activities. These values were 
expressed relative to the Control untreated sample. Experiments were performed in (A) AGS and 











4.2.3 TNF- activates IL23A promoter via the NF-B site 
To further demonstrate the activation of IL23A promoter by NF-B in gastric 
epithelial cells, a reported NF-B binding site in the IL23A minimal promoter reporter 
construct was mutated (Garrett et al., 2008). The result showed that a strong reduction 
in the TNF--responsiveness of IL23A promoter activity was observed in the NF-B-
mutated reporter construct (Figure 4.6). This result indicates that the induction of 
IL23A promoter activity by TNF-is at least mediated through the NF-B binding 
site. Interestingly, the mutation of NF-B binding site diminished the activating 
effects of RUNX3 (Figure 4.6).  
 
 
Figure 4.6. The activation of IL23A promoter by TNF-α is mediated through NF-κB binding site. 
Left panel depicts the schematic diagram of a series of wildtype and mutant IL23A minimal 
promoter reporter constructs. White ovals on the promoters indicate RUNX binding sites and the 
yellow oval indicates B binding site. These constructs were transfected into AGS cells before 
stimulation with TNF- (10ng/ml) for 24h. The promoter activities were evaluated with luciferase 
assays as described in Figure 3.5. The data are representative of experiments performed in 




The necessity of an intact NF-B site for the full effect of RUNX3 indicates that 
RUNX3’s effect is at least in part coupled to NF-B. Similar observation could be 
made in the context of the minimal promoter, where the IL23A promoter was induced 
strongest in the presence of RUNX3 and TNF- treatment (Figure 4.6). Accordingly, 
the synergistic effect between RUNX3 and TNF- was abolished when RUNX or 
NF-B sites was mutated alone or in combination (Figure 4.6). 
 
4.2.4 The involvement of TLR and NLR pathways in the regulation of IL23A  
The involvement of Toll-like receptors (TLR) and NOD-like receptors in the 
transcriptional regulation of IL23A in leukocytes has been reported previously. In the 
current study, such regulation was also observed in monocytic cell line, THP-1 as 
reported in the previous chapter (Figure 3.9). To investigate the relevance of these 
pathways in the regulation of IL23A in gastric epithelial cells, a screen was performed 
using a combination of TLR/NOD ligands or agonists listed in Table 4.1.  
 
Ligand Receptors Origin of ligand 
Pam3CSK4 TLR 1/2 Bacteria and mycobacteria 
Poly I:C TLR 3 Analog of dsRNA from virus 
LPS TLR 4 Gram negative bacteria 
Flagellin TLR 5 Bacteria 
Zymosan TLR 2/6 Fungi 
R-848 TLR 7/8 Viruses 
iE-DAP NOD1 
Gram negative and some Gram positive 
bacteria 
MDP NOD2 Bacteria 
 
Table 4.1. Summary of the ligands and their origins for different pattern recognition receptor 





The changes in IL23A mRNA levels following treatment with ligands of 
different receptors were shown in Figure 4.7. Unexpectedly, the TLR ligands did not 
have significant effects on IL23A expression in AGS cells (Figure 4.7). On the other 
hand, activating NOD1 using iE-DAP led to a 4-fold induction of IL23A (Figure 4.7). 
These observations indicate that the NOD1 pathway, most commonly activated by 
bacterial pathogens, has a role in the regulation of IL23A in gastric epithelial cells. 
 
 
Figure 4.7. Changes in IL23A expression in response to several ligands and agonists of TLR and 
NLR pathways. AGS cells were incubated with 1g/ml of Pam3CSK4, PolyI:C, LPS, Zymosan, R-
848, Flagellin (100g/ml), iE-DAP (10g/ml) and MDP (50g/ml) for 6h. Cells were harvested and 
IL23A mRNA was measured using qRT-PCR. The values were normalised with GAPDH and 
expressed relative to the mock control calculated by Ct method. Data are presented as means 











4.2.5 H. pylori infection induces IL23A expression 
To further explore the involvement of NOD1 pathway in the activation of 
IL23A, we infected gastric epithelial cells with H. pylori, as it is a known activator of 
the NOD1 pathway and a major bacterial pathogen in the human stomach. To 
establish a suitable bacterial titre for this study, AGS cells were infected with H. 
pylori at different multiplicities of infection (MOI). Figure 4.8 shows that increasing 
MOI of H. pylori resulted in progressively stronger induction of IL23A transcript. 
This result reveals a positive correlation between H. pylori infection and IL23A 
expression in AGS cells. Consistent with the intracellular distribution of NOD1 and 
the need of an active Type IV secretion system for the delivery of iE-DAP, heat-killed 
H. pylori had no effect on IL23A levels. 
 
 
Figure 4.8. H. pylori activates IL23A in a dose-dependent manner. AGS cells were co-cultured 
with different MOIs of live and heat-killed H. pylori for 6h prior quantification of IL23A transcript via 
qRT-PCR. The values were normalised with GAPDH and expressed relative to the MOI0 control 






4.2.6 CagA-status of H. pylori determines the outcome of IL23A induction 
Together with the introduction of iE-DAP into gastric epithelial cells, which 
actives NOD1, H. pylori also delivers the virulence factor CagA (section 4.1.2). To 
examine the effect of CagA on IL23A transcription, AGS cells were infected with 
either a wild type (WT) H. pylori or its CagA-defective isogenic strain (CagA) at 
four different time points. A comparison of the kinetics of IL23A induction resulting 
from the infection of WT and CagA H. pylori revealed that both strains activate 
IL23A mRNA maximally at 6h (Figure 4.9A). However, continual induction of IL23A 
was observed only in the samples treated with wild-type H. pylori at 24h suggesting 
that CagA is critical for sustained induction of this gene (Figure 4.9A). The induction 
kinetics of IL23A in response to H. pylori was compared with that of interleukin-8 
mRNA (IL8), a classical host target gene of CagA (Sharma et al., 1995). This reveals 
that the induction kinetics of IL23A closely resembled that of IL8, suggesting that 






Figure 4.9. Wildtype and CagA strains of H. pylori induction time-course for IL23A and IL8. AGS 
cells were infected with either wildtype (WT) or CagA strains of H. pylori (Hp) at MOI 100 for 0h, 
6h, 12h and 24h prior to the assessment of IL23A (A) and IL8 (B) transcripts by qRT-PCR. The 




To demonstrate the specificity of RUNX3’s action, changes in the expression of IL8 
were compared against that of IL23A. Although the induction of IL8 by H. pylori 
followed very similar kinetics to that of IL23A, it was clearly not dependent on 
RUNX3 (Figure 4.10). This suggests that RUNX3 may be involved in the regulation 





Figure 4.10. RUNX3 specifically enhanced H. pylori-induced IL23A but not IL8 in gastric epithelial cells. 
AGS cells were infected with either WT or ΔCagA H. pylori for 6h prior measurement of IL23A and IL8 
transcripts by qRT-PCR. The normalised values are expressed relative to uninfected control. 
 
As CagA is known to interact with and acts through SHP2 in gastric epithelial cells, 
its involvement was examined using specific inhibitor. Treatment with 50M of 
SHP2 inhibitor (NSC87877) abolished CagA-dependent activation of IL23A by 
wildtype H. pylori (Figure 4.11). These data indicate that prolonged activation of 







Figure 4.11. IL23A induction by H. pylori requires activation of SHP-2/ERK pathway by 
oncoprotein CagA. AGS cells were incubated with 50M of SHP2 inhibitor (NSC87877) for 3h 
prior to the infection with wildtype (WT) or CagA strains of H. pylori (Hp) at MOI100 or vehicle 
(Mock) for 18h. The qRT-PCR values of IL23A were normalised with GAPDH and were expressed 
relative to the basal values of mock-infected samples (means ± SEM). Data presented are 
collected from three separate experiments and Student t-test were performed (*p<0.05). 
 
4.2.7 Induction of IL23A is observed in multiple gastric epithelial cell lines 
Having established that TNF- and H. pylori are the activating stimuli for 
IL23A in AGS cells, a collection of nine gastric epithelial cell lines were next tested to 
determine if these observation are reproducible. Remarkably, TNF- and H. pylori 
induce IL23A in a majority of these gastric cancer cell lines (Figure 4.12). 
Furthermore, similar effects were also observed in two non-cancerous gastric 
epithelial cell lines, HFE-145 and GES-1 (Figure 4.12). The conservation of these 
regulatory mechanisms across different gastric epithelial cell lines strongly suggests 
the central roles for H. pylori and TNF- in the regulation of IL23A in this cell type. 
These results implicate that IL23A plays a significant role in the inflammatory cascade 





Figure 4.12. TNF- and H. pylori upregulate IL23A over multiple gastric epithelial cell lines. Two 
non-cancerous and seven cancerous gastric epithelial cell lines were stimulated with TNF- 
(10ng/ml) or infected with wildtype H. pylori (MOI100) for 6h. IL23A mRNA levels were 
determined by qRT-PCR. The values were normalised with GAPDH and expressed relative to the 
Mock control of each cell line. Data are presented as means ± SEM (n=3). 
 
4.2.8 Inflammatory stimuli-induced IL23A is significantly enhanced by RUNX3 
Given the significance of TNF- and H. pylori on IL23A activation, the 
cooperation of these signals with RUNX3 was investigated. The results showed that 
in addition to the cooperation between TNF- and H. pylori, the presence of RUNX3 
resulted in a marked enhancement in the induction of IL23A (Figure 4.13A). This 
synergistic effect between RUNX3, TNF- and H. pylori on IL23A was particularly 
clear at the protein level (Figure 4.13B). Notably, this cooperative effect was entirely 
absent in the AGS cell line that ectopically expressed the RUNX3
R178Q
 DNA-binding 
defective mutant. These results indicate RUNX3 is a critical requirement for a strong 
induction of IL23A when AGS gastric epithelial cells are challenged by the pro-









Figure 4.13. The expression of IL23A in response to RUNX3, TNF-and H. pylori. (A) AGS cells 
were transduced with Lenti-control, RUNX3 or RUNX3
R178Q
 lentiviruses for 48h preceding the 
treatment with 10ng/ml of TNF- and/or infection with H. pylori at MOI100 for 6h. Transcripts of 
IL23A were determined by qRT-PCR and the data presented are from three independent 
experiments (means ± SEM). (B) AGS cells transduced with the same series of lentiviruses were 
cultured with TNF- and/or infected with H. pylori (MOI100) for 18h. Whole cell lysates were then 
prepared and analysed for IL23A, RUNX3 and -tubulin (loading control) protein expression using 
Western blot. 
 
4.2.9 Knockdown of RUNX3 and RUNX1 confirm their positive roles on IL23A 
In the previous chapter, promoter reporter study revealed that RUNX1 is also 
a transactivator of IL23A promoter (Figure 3.7). Therefore, to validate the role of 
RUNX proteins in mediating TNF-/H. pylori induction of IL23A, an RNAi 
knockdown experiment targeting RUNX3 and RUNX1 was performed in an 
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untransformed gastric epithelial cell line, HFE-145 that expresses both RUNX 
proteins. The results reveal that RNAi targeting of either RUNX3 or RUNX1 led to a 
significant reduction in IL23A induction in HFE-145 cells co-treated with TNF- and 
H. pylori, compared with the cells targeted by control siRNA (Figure 4.14A). 
Concurrent targeting of RUNX3 and RUNX1 further reduced the response of IL23A to 
TNF-/H. pylori, confirming that both RUNX members play overlapping roles in the 
mediation of TNF-/H. pylori regulation of IL23A (Figure 4.14). The RNAi 
knockdown of RUNX3 and RUNX1 were confirmed by quantitative RT-PCR and 
Western blot (Figures 4.15A and 4.15B). Taken together, these studies support a 
positive role of RUNX3 and RUNX1 on the regulation of IL23A when gastric 




Figure 4.14. The effects of RNAi knockdown for RUNX3 and RUNX1 on IL23A. HFE-145 cells 
were transiently transfected with 20pmoles control siRNA (siCtrl) or 5pmoles RUNX3 siRNA 
(siRX3) and/or 15pmoles RUNX1 siRNA (siRX1) for 48h preceding infection with H. pylori (Hp) at 
MOI100 and stimulation with TNF- (10ng/ml) for 6h. The transcripts of IL23A were measured by 
qRT-PCR. The values were normalised to those of GAPDH and were expressed relative to siCtrl 
Mock sample. (means ± SEM; n=3). Data are compiled from three separate experiments and 















Figure 4.15. The degree of RNAi knockdown for RUNX3 and RUNX1 in HFE-145 cells. (A) The 
normalised mRNA levels of RUNX3 and RUNX1 in the same samples described in Fig. 4.14 were 
measured by qRT-PCR and expressed relative to the basal values of siCtrl sample (means ± 
SEM; n=3). (B) Corresponding changes in RUNX3, RUNX1 and -tubulin (loading control) protein 
expression were analysed from whole cell lysates by Western blot. 
 
 
4.2.10 The induction of IL23A in AGS does not result in the secretion of IL-23 
To investigate if the expression of IL23A in AGS cells is translated to the 
secretion of the heterodimeric cytokine IL-23, of which IL23A is a subunit, the 
supernatants collected from resting and stimulated AGS cells were subjected to 
enzyme-linked immunosorbent assay (ELISA). Strikingly, in stark contrast to the 
robust secretion of IL-23 in LPS-stimulated THP-1 cells, the levels of IL-23 in AGS-
derived supernatants could not be detected even in the presence of all identified 
activating signals (Figure 4.16A). A possible explanation for the absence of secreted 
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IL-23, despite robust expression of IL23A, is the insufficient expression of its partner 
subunit, IL12B. To investigate this, the mRNA level of IL12B was measured in 
resting and treated AGS cells. Indeed, the partner subunit IL12B is neither expressed 
nor induced by any of the signals (Figure 4.16B). Together, these observations 







Figure 4.16. The expression of the heterodimeric IL-23 (IL23A/IL12B) in AGS cells. (A) AGS cells 
were transduced with lentiviruses encoding Lenti-Control, Lenti-RUNX3, Lenti-RUNX3
R178Q 
for 
48h preceding TNF- (10ng/ml) and/or H. pylori (MOI100) stimulation for 24h. Supernatants were 
then harvested and subjected to sandwich ELISA for the quantification of IL-23 secretion. (B) The 
infected AGS cells as described above were stimulated with TNF-/or H. pylori for 6h. IL12B 
mRNA was quantitated using qRT-PCR and the values were normalised with GAPDH and 





As an extension from the earlier observation that IL23A is a target gene of 
RUNX3, this chapter establishes the physiological signals that regulate IL23A 
expression in gastric epithelial cells. In line with the findings by other groups, IL23A 
is positively regulated by NF-B signaling in THP-1, human acute monocytic 
leukemia cell line (Figure 3.9). Thus, different inflammatory stimuli that activate the 
NF-B pathway were explored in gastric epithelial cell lines.  
NF-B-activating cytokines TNF-, IL-1 and IL-1 were found to be 
inducers of IL23A (Figure 4.3). TNF- and IL-1 are produced in response to bacterial 
infection, inflammatory and other stimuli primarily by cells of the immune system 
such as macrophages and T and B lymphocytes (Burchett et al., 1988). These 
cytokines are involved in coordinating inflammatory response and host defence 
mechanisms against pathogens (Elkon et al., 1997; Sambhi et al., 1991; Wong and 
Goeddel, 1986; Yamada et al., 2000). Furthermore, TNF- and IL-1 belong to a 
group of cytokines that stimulate acute phase reaction and initiate a cascade of 
cytokine production for the recruitment of immune cells for host defence (Warren, 
1990). The activation of IL23A by these upstream signals implicates a role for IL23A 
in host acute inflammatory responses against pathogen challenge. On the other hand, 
the lack of induction for IL23A observed for IFN-γ, IL-6 and TGF-β does not rule out 
their involvement in this regulation (Figure 4.3). It is possible that the corresponding 
cytokine receptors are absence in gastric epithelial cells which causes them 
hyporesponsive to the signals. To rule out the involvement of other cytokines in the 




An intriguing observation is that RUNX3 cooperates strongly with TNF- in 
the induction of IL23A in gastric epithelial cells (Figure 4.4 and 4.5). Together with 
the analysis of proximal NF-B and RUNX consensus binding sites in IL23A 
promoter (Figure 4.6), the possibility of cooperativity between RUNX3 and TNF-
/NF-B on the transcription of IL23A is further strengthened. In addition, the robust 
expression of IL23A protein induced by RUNX3 and TNF- underscores the 
importance of this synergistic cooperation (Figure 4.6). Critically, the above findings 
revealed that gastric epithelial cells are a novel cell type that expresses IL23A. 
Given that NF-B family members are nuclear effectors of PRRs pathways, 
the inability of various ligands of these receptors to activate IL23A is surprising 
(Figure 4.7) (Abreu, 2010; Wells et al., 2010). The reason for this could be the 
expression of PPRs in gastric epithelial cells requires additional challenges, e.g. 
pathogen infection. The lack of co-receptors such as CD14 and MD2 in gastric 
epithelial cells may also render them hyporesponsive to TLR ligands (Ferrero, 2005; 
Watanabe et al., 2010). The NOD1 agonist, iE-DAP, was the exception among all 
ligands tested in its ability to activate IL23A in AGS cells (Figure 4.7). Unlike NOD2 
which is a general sensor for bacteria, NOD1 recognises a subset of microbes that 
contain the dipeptide iE-DAP, such as H. pylori, an important pathogen in the 
stomach (Boughan et al., 2006; McDonald et al., 2005; Viala et al., 2004; Watanabe et 
al., 2010). The specific induction of IL23A by NOD1, together with the notion that the 
same pathway is required for activation of the classical host immune cytokine IL-8, 
implicate that IL23A belongs to part of a general immune response that targets 
specific subset of pathogens, e.g. H .pylori (Grubman et al., 2010).   
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The positive correlation between the degree of H. pylori infection and IL23A 
mRNA levels implicates that IL23A may be required for evoking a strong immune 
response for bacteria clearance (Figure 4.8). Notably, the lack of induction of IL23A 
in AGS cells by heat-killed H. pylori suggests that it is an active and energy-
dependent process (Figure 4.8). However, the possibility that heat denatures some 
bacterial agonists require for the induction of IL23A cannot be ruled out. 
Nevertheless, the delivery of bacterial products into host cells requires adhesion of 
live H. pylori to the host cells for the insertion of the Type IV secretion system (Kwok 
et al., 2007; Rohde et al., 2003). The active induction of IL23A by H. pylori indicates 
the involvement of Type IV secretion system (Figure 4.8).  
CagA protein delivered by H. pylori into the host cells was crucial for 
sustained induction of IL23A (Figure 4.9). As discussed in Section 1.3.1, CagA-
positive strain of H. pylori is more virulent compared to CagA-negative strain. The 
prolonged induction of IL23A in gastric epithelial cells may be necessary to mount a 
proper immune response against CagA-positive H. pylori. The CagA-dependent 
induction of IL23A was suppressed when SHP2 activity was inhibited implicating that 
injected CagA protein is phosphorylated in AGS cells that leads to preferential 
activation of ERK1/2 signaling (Figure 4.11). Although, the transcription factors that 
are activated downstream of CagA/SHP2/ERK pathway remains unknown, ETS 
family of transcription factors which are well-known to be activated by ERK could be 
one of them (Foulds et al., 2004; Paumelle et al., 2002). Interestingly, ETS1 is also 
known to interact with RUNX1 protein on Mo-MLV and TCR enhancers in immune 
cells (Sun et al., 1995; Wotton et al., 1994). Therefore, the involvement of ETS1 and 
its cooperation with RUNX proteins in CagA/SHP2-dependent activation of IL23A in 
gastric epithelial cells will be worth investigating in the future. As inhibitor often has 
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broad spectrum effects, the involvement of SHP2 in the induction of IL23A by CagA 
requires further confirmation using RNAi specific targeting of SHP2 in the cells. 
The conservation of the effects for TNF- and H. pylori on IL23A observed in 
different gastric epithelial cell lines implicates that IL23A is part of the natural host 
immune response of gastric epithelial cells (Figure 4.12). More importantly, the 
induction of IL23A by TNF- and H. pylori was markedly potentiated by RUNX3, 
indicating a critical role of RUNX3 for the cooperative activation of IL23A 
expression (Figure 4.13). The ineffectiveness of RUNX3
R178Q
 suggests that the 
synergistic cooperation between RUNX3 and inflammatory stimuli happens at the 
level of transcriptional activation and requires the binding to DNA. Reduction of 
IL23A levels upon the knockdown of RUNX3 further confirmed its positive role in 
the regulation of IL23A in the presence of TNF- and H. pylori (Figure 4.14). These 
observations implicate the importance of RUNX3 in the regulation of IL23A during 
inflammation and infection. 
An intriguing observation is that IL23A expressed in AGS cells was not 
secreted in the known heterodimeric form, IL-23 (Figure 4.16A). This was likely due 
to the absence of the partner subunit IL12B (Figure 4.16B). A similar observation has 
been reported in intestinal epithelial cells where IL23A was expressed in the absence 
of IL12B (Maaser et al., 2004). Other studies have shown that IL23A was up-
regulated in synovial fibroblasts and colonic subepithelial myofibroblasts, especially 
in disease states (Kim et al., 2007a; Liu et al., 2007; Zhang et al., 2005). However, 
little is known about the function of IL23A in these tissue contexts. In mice, gene 
targeting of the cytokine and its receptor generally have same phenotypes. However, 







 mice. Specifically, they reported that the histological scores of Il23a
-/-
 
mice were reproducibly less severe than those of Il23R
-/-
 mice in chemical-induced 
colitis (Cox et al., 2012). These observations, together with those observed in the 
current study suggest that IL23A may functionally interact with proteins other than 
IL12B to mediate signals distinct from that of IL-23, possibly through another IL-
23R-associated heterodimeric receptor.    
 Findings in this chapter revealed that H. pylori infection and TNF- are two 
major upstream signals for regulating IL23A expression in gastric epithelial cells. 
Interestingly, the cooperation between RUNX3, TNF- and H. pylori significantly 
enhanced IL23A expression in gastric epithelial cells. The regulation of IL23A by 
TNF- and H. pylori in these cells implicates that this protein is part of the host 
defence mechanisms. Inactivation of RUNX3 that is frequently observed during 
gastric carcinogenesis may result in lower production of IL23A by gastric epithelial 
cells leading to defective host immune response against pathogen infection. The data 
presented in this study further suggests that IL23A is not secreted as the known 
heterodimeric form (IL-23) in AGS cells. There is a possibility that this protein is not 
secreted by gastric epithelial cells, or it might be secreted in an unknown form. Thus, 
the secretion of IL23A protein and the functional consequences of the above 






The functional effects of gastric epithelial cell-





5.1.1 The discoveries and known functions of IL23A/IL-23 
IL23A was discovered on the basis of the structural resemblance of its 
predicted tertiary structure to that of IL12A, which together with IL12B forms the 
heterodimeric cytokine, IL-12 (Oppmann et al., 2000). Further characterisation 
revealed that IL23A has no biological activity of its own, but when dimerised with 
IL12B they form a novel cytokine, IL-23 with distinct biological activities (Figure 
1.5). Although IL23A possesses a signal peptide within its N-terminal region that is 
characteristic of a secretory protein, it was demonstrated that the secretion of IL23A is 
only efficient in the presence of its partner subunit, IL12B (Oppmann et al., 2000). 
Therefore, it was suggested that cellular secretion of IL23A takes place only 
following dimerisation with an interacting partner protein (Oppmann et al., 2000). 
Similar to IL-12, IL-23 is usually secreted by activated antigen presenting 
cells (APC), in particular dendritic cells (DC) and macrophages (Hsieh et al., 1993; 
Macatonia et al., 1995; Oppmann et al., 2000). Studies have defined IL-12 as an 
important factor for the differentiation of IFN- producing Type I-helper T cells (TH1) 
cells from naïve T cells (Gazzinelli et al., 1993; Hsieh et al., 1993; Manetti et al., 
1993; O'Garra and Arai, 2000; Seder et al., 1993; Tripp et al., 1993). Therefore, the 
physiological function of IL-23 was first examined in the context of T cell 
proliferation and IFN- secretion. It was found that recombinant human IL-23 induced 
the proliferation of CD45RO memory T cells and the secretion of IFN- after 
prolonged CD3 and CD28 co-activation (Oppmann et al., 2000). These immune 
responses were effectively blocked by incubation with neutralising antibodies against 
the IL12B subunit (common partner for IL-23 and IL-12) and its receptor IL12R1 
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but not IL12A (the unique subunit for IL-12) suggesting the above effects are specific 
to IL-23 (Oppmann et al., 2000). 
Further insights into the unique function of IL-23 were generated in studies of 
the IL23a knockout mouse which revealed a crucial role in the development and 
effector functions of TH17, a novel helper T cell subset characterised by its secretion 
of IL-17  (Langrish et al., 2005; McGeachy et al., 2007; McGeachy et al., 2009). This 
prompted the purification of human TH17 cells for further characterisation of IL-23 
function. It is now well established that IL-23 is critical for the survival and 
proliferation of human TH17 cells and their production of IL-17 for the recruitment of 
neutrophils to the site of microbial infection (Acosta-Rodriguez et al., 2007; Cruz et 
al., 2006; Kolls and Linden, 2004; Meeks et al., 2009; Stockinger and Veldhoen, 
2007; Volpe et al., 2008; Wilson et al., 2007).  
Given the importance of IL-23’s effects on T cells, the functional 
consequences of gastric epithelial cell-derived IL23A will be tested on human 
(peripheral blood mononuclear cells) PBMC-derived T cells by employing a similar 
approach adopted by earlier studies on the characterisation of the heterodimeric 








5.2.1. Accumulation of intracellular IL23A in AGS cells 
In the previous chapter, it was revealed that despite a robust expression of 
IL23A following its induction by RUNX3, TNF-and H. pylori, no secretion of IL-
23 was observed, possibly due to the absence of IL12B. To confirm the above 
observation, a panel of gastric epithelial cell lines were tested for the secretion of IL-
23 upon TNF- treatment with ELISA. In line with the previous observation, the 
absence of secreted IL-23 was not restricted to AGS cells, but consistently observed 
in multiple gastric cancer cell lines (Figure 5.1). However, these assays were 
performed using a ‘sandwich’ ELISA specific for the detection of IL23A/IL12B (IL-
23) heterodimer. Therefore, the possibility of the secretion of IL23A from gastric 




Figure 5.1. The induction of heterodimeric IL-23 by TNF- in multiple gastric epithelial cell lines. 
Gastric epithelial cell lines AGS, MKN28, MKN45 and KATOIII were treated with 10ng/ml of TNF-
 whereas THP-1 was treated with 1g/ml of LPS for 24h. Supernatants collected from these 




To further investigate the above possibility, AGS cells were stimulated to 
express IL23A in the presence or absence of a secretion-blocking agent, fungal 
macrocyclic lactone Brefeldin A (BfdA). The BfdA has proved to be a potent 
inhibitor of protein secretion in the endomembrane system of mammalian cells. 
(Dinter and Berger, 1998; Fujiwara et al., 1988; Klausner et al., 1992; Misumi et al., 
1986; Nylander and Kalies, 1999; Sciaky et al., 1997). Newly synthesised secretory 
proteins are docked to the rough endoplasmic reticulum (ER) and transited through 
the Golgi apparatus before being exported to the cell surface (Palade, 1975). 
Treatment with BfdA causes the trans-Golgi network to collapse and thus the 
accumulation of proteins inside the rough ER (Lippincott-Schwartz et al., 1991; 
Reaves and Banting, 1992).  
To assess the secretion of IL23A, AGS cells transduced with lentiviruses 
encoding Lenti-Control, Lenti-RUNX3 or Lenti-RUNX3
R178Q
 were stimulated with 
TNF- and H.pylori, before blocking with BfdA for duration of 8h. The results 
presented in Figure 5.2 revealed that inhibition of protein secretion by BfdA led to a 
clear induction of IL23A in Lenti-RUNX3 infected AGS cells even in the absence of 
inflammatory stimuli, compared with the unstimulated control (-BfdA) (Figure 5.2, 
lanes 3 and 4). Furthermore, a clear increase in intracellular IL23A protein was 
observed in the H. pylori- and TNF--stimulated Lenti-Control and Lenti-
RUNX3
R178Q
 samples (Figure 5.2, lanes 7, 8, 11 and 12). Consistent with this trend, 
the accumulation of IL23A in the cells was markedly higher in the presence of 
RUNX3, TNF- and H. pylori, reflecting their cooperative activation of IL23A 
(Figure 5.2, lanes 9 and 10). Together, these data reveal that the accumulation of 
IL23A following blockade of protein export, hence suggesting its secretion by AGS 




Figure 5.2. The accumulation of intracellular IL23A in AGS cells. AGS cells were transduced with 
lentiviruses expressing Control, RUNX3 or RUNX3
R178Q 
for 48h preceding TNF- (10ng/ml) 
treatment and H. pylori (MOI100) infection for 9h. Brefeldin A (BfdA) solution (1:1000) was added 
into the culture medium at the last 8h before the cells were harvested. Whole cell lysates were 
then prepared and analysed for the expression of IL23A, RUNX3 and -tubulin (loading control) 
using Western blot. A shorter exposure for IL23A protein was included to show the band 


















5.2.2 The accumulation and secretion kinetics of IL23A 
To better understand the kinetics of IL23A accumulation and secretion, AGS 
cells infected with Lenti-RUNX3 virus were treated with TNF- and H. pylori for 
different durations before the blockade of protein export by BfdA in the last 8h. The 
results showed that the accumulation of IL23A protein resulting from the action of 
BfdA could be observed over multiple time points (Figure 5.3). The highest 
accumulation of IL23A protein was observed at 9h following TNF- and H. pylori 
stimulation indicating that the protein was synthesised and secreted within a short 
period of time (Figure 5.3, lanes 3 and 4). These results provide strong evidence for 
the secretion of IL23A by AGS cells upon induction. Furthermore, they revealed that 




Figure 5.3. The accumulation and secretion kinetics of IL23A in AGS cells. AGS was transduced 
with Lenti-RUNX3 virus as described in Fig 5.2 prior TNF- (10ng/ml) and H. pylori (MOI100) 
stimulation for 1h, 10h, 16h, and 25h followed by addition of Brefeldin A (BfdA) solution for 8h 
before the cells were harvested. Whole cell lysates were then prepared and analysed for the 






5.2.3 Neutralising antibody effectively depletes IL23A from culture supernatant 
As a first step towards the functional characterisation of secreted IL23A in the 
supernatant of AGS cells, a monoclonal IL23A-specific antibody was tested for its 
ability to immunodeplete IL23A. The effectiveness of this antibody was assessed on 
its ability to deplete (or “neutralise”) secreted IL-23 in the supernatant of LPS-
activated THP-1. The extent of depletion was measured by IL-23-specific ELISA and 
results revealed a marked decrease in the secreted IL-23 following pre-incubation 
with the anti-IL-23A antibody, compared with an anti-IgG antibody (Figure 5.4). This 
result demonstrates that the anti-IL23A neutralising antibody was effective in 
depleting secreted IL23A and is therefore suitable for functional study of this protein 
in the subsequent assays. 
 
 
Figure 5.4. The effects of IL23A-specific neutralising antibody on secreted IL-23. THP-1 cells 
were stimulated with 1g/ml of LPS for 6h. Supernatants from both stimulated and non-stimulated 
THP-1 cells were harvested and incubated with either 2g/ml of anti-IL23A or IgG control 
antibody for 4h at 37°C. The treated supernatants were then subjected to sandwich ELISA for the 





5.2.4 The activation of T cell proliferation by anti-CD3 antibody 
To establish a T cell model for studying the functional effects of the secreted 
IL23A from gastric epithelial cells, human peripheral blood mononuclear cells 
(PBMC) were treated with an anti-CD3 monoclonal antibody to activate T cells. For 
the purpose of optimising the time frame for T cell proliferation, PBMC were pulsed 
with a fluorescence dye CFSE (carboxyfluorescein diacetate, succinimidyl ester) 
followed by the activation with anti-CD3 in ex vivo culture for three and seven days. 
The results showed that there was no obvious difference in CFSE fluorescence 
intensity in PBMC three days after anti-CD3 activation compared to those at resting 
state (Figure 5.5). In contrast, a clear decrease in CFSE fluorescence was observed at 
day 7 in anti-CD3 activated T cells (Figure 5.5). The shift of cell population towards 
lower CFSE fluorescence intensity indicates that T cell division occurred seven days 
post-stimulation with anti-CD3. Having established seven days is required to achieve 
robust T cells proliferation ex vivo following anti-CD3 activation, this regime will be 








Figure 5.5. The proliferation of anti-CD3 activated T cells derived from human PBMC. PBMC 
harvested from human blood sample was stained with 5M CFSE dye prior to the activation by 
1.1ng/ml of anti-CD3 antibody to stimulate T cell proliferation as described in materials and 
methods (section 2.9.2). Next, 0.2 x 10
6
 of cells were seeded into each 96-well U bottom plate in 
fresh medium and cultured for three and seven days. Analysis of CFSE fluorescence was 
performed by flow cytometry. A gate was set to demarcate the proliferative T cells based on the 














5.2.5 Secreted IL23A stimulates T cell proliferation 
To assess the biological activity of secreted IL23A on T cell proliferation, 
anti-CD3 activated PBMC from four different donors were harvested and co-cultured 
with supernatants of AGS cells treated with either anti-IL23A or anti-IgG neutralising 
antibody. In these four independent experiments, significant variations in the 
proliferative potential of PBMC-derived T cells from different donors were observed 
(Figure 5.6A). This variation could be attributed to the different health statuses of the 
individual donors, which may affect the concentration of different mononuclear cells 
in the PBMC. Notwithstanding these fluctuations, a modest increase in T cell 
proliferation could be observed when cultured in the supernatants derived from AGS 
cells stably expressing RUNX3 in these four donors (Figure 5.6A). Importantly, the 
increase in T cell proliferation was specifically blocked in the same supernatants that 
were neutralised with anti-IL23A antibody, but not in anti-IgG control treated samples 
(Figure 5.6A). In contrast, the proliferative populations in anti-IgG- and anti-IL23A-
treated supernatants were indistinguishable in the cases of Lenti-Control and Lenti-
RUNX3
R178Q
 infected AGS cells, which is consistent with the lack of secreted IL23A 
in these samples (Figure 5.6A). The T cell proliferation assay for each PBMC donor 
was performed in triplicates and the data from one representative donor were 
presented in Figure 5.6B. Together, these data suggest that RUNX3-induced IL23A in 













Figure 5.6. The effects of supernatants derived from AGS cells on T cell proliferation. (A) CFSE-
stained PBMC cultured in the presence of anti-CD3 (1.1ng/ml) was incubated with the 
supernatants harvested from AGS cells infected with Lenti-Control, Lenti-RUNX3 or Lenti-
RUNX3
R178Q 
viruses that were treated with either 2g/ml of anti-IgG or anti-IL23A antibody. PBMC 
was cultured in AGS-derived supernatants for 7 days prior to analysis by flow cytometry. Due to 
the large variation in the extent of T cell proliferation between donors, the gating for proliferative T 
cells was set based on the Lenti-Control sample within each donor. The experiments for each 
PBMC donor were performed in triplicates and the flow cytometry plots from one replicate were 
presented. (B) Percentage of proliferating cells in response to AGS-derived supernatants. Data 
from a representative donor was presented and expressed as percentage of dividing cells. Data 




5.2.6 IFN- production of T cells is modulated by secreted IL23A 
To gain further insights into the effects of AGS-derived IL23A on activated T 
cells, the culture supernatants of T cells were analysed for cytokine contents seven 
days after ex vivo culture. As IFN- is a signature cytokine produced by TH1 cells and 
IL-17 marks TH17 cells, the secretion of these two cytokines were measured in our 
study. As shown in Figure 5.7A, the level of IFN- in the T cell supernatant 
stimulated with Lenti-RUNX3 sample was significantly reduced following the 
depletion of IL23A by anti-IL23A antibody. Such a reduction was not observed in 
control samples in which activated T cells were cultured with supernatants from 
Lenti-Control and Lenti-RUNX3
R178Q




Figure 5.7. The secretion of IFN- and IL-17 by T cells in response to various supernatants of 
AGS cells. The supernatants from T cells at seven days post-stimulation by the supernatants 
derived from AGS cells infected with Lenti-Control, Lenti-RUNX3 and Lenti-RUNX3
R178Q
 viruses 
that were pre-treated with 2g/ml anti-IgG or anti-IL23A antibody. The supernatants from cultured 
T cells were collected and subjected to ELISA for quantification of (A) IFN- and (B) IL-17. Data 
were expressed relative to anti-IgG of each donor and presented as means ± SEM (n=3). ** p < 







Notably, the secretion of IL-17 by T cells was not altered in the presence of IL23A-
specific neutralising antibody in the Lenti-RUNX3 sample (Figure 5.7B). This is 
surprising as IL-17 is normally produced by T cells in response to stimulation by the 
heterodimeric IL-23. The changes in the production of IFN- and IL-17 were 
consistently observed in PBMC derived from four independent donors (Figure 5.8A 
and 5.8B). The data provides evidence that AGS-derived IL23A plays a role in 







Figure 5.8. The secretion of IFN- and IL-17 by T cells derived from different donors in response 
to supernatants from Lenti-RUNX3 sample. T cells derived from PBMC of different donors were 
stimulated with supernatants derived from AGS cells infected with Lenti-RUNX3 viruses for 7 
days. These supernatants were pre-treated with 2g/ml anti-IgG or anti-IL23A antibody. The 
supernatants of cultured T cells were collected and subjected to ELISA for quantification of (A) 
IFN- and (B) IL-17. Data presented were expressed relative to those of anti-IgG of each donor as 




The discovery of the expression of IL23A in gastric epithelial cells upon 
synergistic induction by RUNX3, TNF- and H. pylori raises important questions. H. 
pylori induces stomach inflammation by triggering host immune response whereas 
TNF- is a host cell factor activated during infection and is crucial for coordinating 
immune response (Elkon et al., 1997; Naumann and Crabtree, 2004; Pasparakis et al., 
1996; Peek and Crabtree, 2006; Sambhi et al., 1991; Wong and Goeddel, 1986). The 
cooperation of RUNX3 with these key inflammatory signals implicates a potential 
communication between epithelial cells and immune cells through IL23A. This 
chapter addresses the functional effects of IL23A regulated by RUNX3 and its 
contribution to T cell response. 
The lack of secretion of IL-23 by gastric epithelial cell lines has prompted the 
investigation of IL23A secretion using a protein secretion blocker (Figure 4.16A and 
5.1). Inhibition of intracellular IL23A protein trafficking by BfdA resulted in a robust 
accumulation of this protein, suggesting that IL23A is targeted for secretion in AGS 
cells (Figure 5.2 and 5.3). However, the above observation does not rule out the 
possibility of IL23A being targeted to the plasma membrane of the cells as both 
secretory and transmembrane proteins share the same transportation pathway that is 
targeted by BfdA. Nevertheless, solubilisation of the membrane proteins using a 
stronger lysis method did not result in greater level of IL23A protein detected 
compared to current lysis method (data not shown). Moreover, it was reported that 
IL23A contains a secretory signal peptide but lack transmembrane domain (Inoue, 
2010). Therefore, our results suggest that AGS-derived IL23A is most likely a 
secretory protein rather than a membrane-bound surface protein. The induction time-
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course experiment showed that IL23A was expressed and secreted at an early time 
point (Figure 5.3). This temporal pattern of IL23A secretion implicates that this 
protein is part of the acute inflammatory response against microbial infection such as 
H. pylori. Given the paradoxical roles of IL23A in host defence mechanism and 
autoimmunity in the gastrointestinal tract (section 1.5); it is of utmost importance to 
explore the functional relevance of this protein in gastric epithelial cells. 
The immunoregulatory effects of the secreted IL23A in gastric epithelial cells 
was investigated in an ex vivo culture system that employs T lymphocytes as 
responder cells. This approach will shed light on the existence of IL23A by the 
measureable function on T cell response. PBMC was chosen in this study as it 
contains a mixture of T and B lymphocytes, granulocytes and monocytes. The 
presence of these cells may be necessary for the amplification of T cell response, and 
is therefore a suitable platform for the exploration of IL23A’s effect. Using anti-CD3 
activated T cells derived from PBMC, a proliferative signal on these cells was 
observed from IL23A-containing supernatants derived from gastric epithelial cells 
(Figure 5.6A and 5.6B). Importantly, this enhanced proliferation could be blocked by 
an anti-IL23A neutralising antibody, hence confirming the specificity of IL23A’s 
effect. Unlike anti-CD3 which is a general inducer for T cell proliferation, RUNX3-
induced IL23A resulted in a modest increase in the percentage of proliferative T cell 
population in addition to the dramatic elevation caused by anti-CD3 (Figure 5.5 and 
5.6A) (Frauwirth and Thompson, 2002; Trickett and Kwan, 2003). This interesting 
observation suggests that the modest increase in the percentage of proliferative 
population may be attributed to a unique subset of responsive T cells. Thus, 
identification and purification of this specific subset of responder T cells would 
potentially demonstrate a clearer effect of IL23A derived from AGS cells. 
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As IL23A secretion has been shown to be dramatically induced by RUNX3, 
TNF- and H. pylori, supernatants from cells stimulated by these three activating 
signals would result in greater responsiveness by T cells. However, the drawback of 
using PBMC as a model is that these cells respond strongly to inflammatory stimuli 
(e.g. bacteria) especially in the presence of monocytes (Zareie et al., 2001; Ziegler-
Heitbrock, 2007). This strong immune response caused by bacteria may mask the true 
biological effects of IL23A. Consequently, TNF-- and H. pylori-treated samples 
could not be included in the current experimental setup; the modest differences 
observed for T cell proliferation could be attributed to the low level of IL23A secreted 
by AGS cells in the absence of these inflammatory stimuli (Figure 5.2). To enhance 
the level of IL23A and avoid non-specific effects from PBMC, purification of IL23A 
from the supernatant of gastric epithelial cells will be required to concentrate the 
amount of secreted IL23A in order to induce greater T cell response.   
In addition to the proliferative properties of T cells, measurement of cytokine 
secretion from T cells will also shed light on the effects of IL23A on the different 
subsets of T lymphocytes. Intriguingly, a significant difference was observed for the 
secretion of IFN- but not IL-17 by T cells in response to IL23A (Figure 5.7 and 5.8). 
This is unexpected as IL-23 is critical for the differentiation of IL-17 secreting TH17 
cells (Langrish et al., 2005; McGeachy et al., 2007; McGeachy et al., 2009). These 
data provide further evidence that gastric epithelial cell-derived IL23A plays a 
different role in eliciting T cell response as compared to IL-23 secreted by monocytes.  
In summary, these functional studies further strengthen the secretion of IL23A 
and therefore the importance of its regulation by RUNX3, TNF- and H. pylori in 
gastric epithelial cells. It is possible that RUNX3 is involved in the host inflammatory 
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response against pathogens through the regulation of IL23A secreted by gastric 
epithelial cells. The above phenomenon observed in T cells may reflect the 
communication between gastric epithelial cells and immune cells via IL23A. 
Therefore, we postulate that in addition to its previously reported effects on epithelial 
cell growth and apoptosis, RUNX3 promotes an effective inflammatory response by 
activating IL23A in response to inflammatory signals and infection. Studies have 
reported that efficient secretion of IL23A requires dimerisation with a partner subunit 
(Kopp et al., 2003; Oppmann et al., 2000). For instance, secretion of IL-23 by 
keratinocytes was promoted in transgenic mice that constitutively express IL12B 
(Kopp et al., 2003). However, there is no report to date about the association of 
IL23A with other subunits of the IL-12 family other than IL12B. It is possible that the 
partner subunit of IL23A in gastric epithelial cells has yet to be discovered and the 





General discussion and future works 
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6.1 Summary of findings 
The current study establishes IL23A to be a novel target gene of the 
transcription factor and gastric tumour suppressor RUNX3 in gastric epithelial cells.  
RUNX3 was found to promote the transcription of IL23A in the majority of gastric 
cancer cell lines tested in this study. Through a combination of biochemical and cell 
biological studies, it demonstrated that RUNX3 binds to three RUNX binding site in 
the proximal IL23A promoter to transactivate IL23A transcription. In elucidating the 
upstream signals that regulates this gene in gastric epithelial cells, it was found that 
the proinflammatory cytokine TNF- and gastric pathogen H. pylori act as potent 
activating signals for IL23A in a wide range of gastric epithelial cells. It was shown 
that TNF- mediates its activation of IL23A via a conserved NF-B site at the 
proximal promoter.  Activation of the NF-B pathway by NOD1 also appears to play 
a role in the transient activation of IL23A transcription following H. pylori infection. 
However, sustained induction of this gene is determined by the activation of SHP2 
pathway and the presence of oncoprotein CagA, thereby revealing an intriguing two-
phase induction mechanism. Importantly, RUNX3 is a critical requirement for a 
synergistic induction of IL23A transcript and protein by TNF- and H. pylori. 
Furthermore, promoter studies and RNAi experiments revealed that RUNX1 plays 
similar but non-identical role as RUNX3 in the regulation of IL23A in gastric 
epithelial cell lines. Although the robust expression of IL23A promoted by RUNX3, 
TNF- and H. pylori identifies gastric epithelial cell as a novel source cell of IL23A, 
it does not appear to be secreted in its known heterodimeric form (i.e. IL-23). 
Nevertheless, the secretion of IL23A is supported by its rapid accumulation following 
the blockade of cellular protein export by Brefeldin A. Furthermore, stimulating the 
human T cells with secreted IL23A derived from AGS cells reveals putative functions 
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for this protein in promoting T cell proliferation and IFN production. Collectively, 
these findings indicate that RUNX3 as well as RUNX1 may play a hitherto 
unappreciated role in modulating mucosal immune response via a direct regulation of 
IL23A during gastric inflammation and infection by H. pylori. As H. pylori-induced 
inflammation represents a major risk factor in gastric cancer, these findings suggest 
RUNX3 may exert its tumor suppressive effect in part through an influence in gastric 
mucosal immunity and inflammation. Based on the data presented in this study, a 




Figure 6.1. A model illustrating the regulation of IL23A by RUNX3 and inflammatory 
signals triggered by TNF- and H. pylori in gastric epithelial cells. ‘TNFR’ and ‘PGN’ 





6.2 Significance of findings and future works 
Host immunity and inflammation are intimately linked with cancer. The long-
held theory of immune surveillance proposes that cells and tissues are constantly 
monitored by an ever-alert host immunity that is responsible for identifying and 
destroying the vast majority of incipient cancer cells, and thus nascent tumour 
(Burnet, 1970; Thomas, 1959). This theory was firmly supported by substantial 
studies from genetically engineered mice and clinical epidemiology, which showed 
that host immunity operates as a significant barrier to tumour formation and 
progression (Bindea et al., 2010; Ferrone and Dranoff, 2010; Kim et al., 2007b; 
Nelson, 2008; Smyth et al., 2006; Teng et al., 2008). On the other hand, tumour-
associated inflammatory response had the unanticipated, paradoxical effect of 
enhancing tumorigenesis, in effecting incipient neoplasias to acquire the hallmark 
capabilities of cancer. Subsequent studies on the intersections between inflammation 
and cancer have produced abundant and compelling evidence of the functionally 
important tumour-promoting effects of host immunity (Colotta et al., 2009; DeNardo 
et al., 2010; Grivennikov et al., 2010; Qian and Pollard, 2010). Given the significance 
of this causal relationship, tumour-promoting inflammation and evasion of tumour 
immunity are now regarded as emerging hallmarks of cancer (Hanahan and Weinberg, 
2011). The growing appreciation of the immunological dimensions of cancer reflects 
the fact that host immunity is a double-edge sword and homeostatic balance of 
immune response is therefore important.  
The strong connection between chronic inflammation and cancer is particular 
apparent in the gastrointestinal tract, where microbial challenge is frequent. The 
monolayer of epithelial cells that lines the gastrointestinal tract not only provides a 
physical barrier but also serves immunoregulatory functions. As gastric cancer is an 
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epithelial-derived disease, understanding the immune-related function of gastric 
epithelial tumour suppressor RUNX3 is therefore of specific relevance. The findings 
presented in this thesis reveal a novel role for RUNX3 in the regulation of the 
cytokine gene IL23A in gastric epithelial cells, thereby implicating a role for RUNX3 
in the modulation of gastric mucosal immunity.  
In elucidating the molecular machinery for the transcriptional regulation of 
IL23A, RUNX3 was found to be critical for the amplification of TNF- activation of 
NF-B pathway. Conversely, RUNX3’s own effect in the absence of exogenous 
stimulation also appears coupled with NF-B. Together; these observations signify a 
strong cooperation between NF-B and RUNX3 as well as RUNX1. Indeed, 
cooperation between classical tumour suppressor such as p53 and immune signaling 
has recently been reported (Puszynski et al., 2009; Schneider et al., 2010; Tergaonkar 
and Perkins, 2007). While the precise mechanism remains obscure, it is noteworthy 
that the RUNX- and NF-B-responsive elements are in close proximity on the IL23A 
promoter, which may enable direct interaction. In future studies, this possibility could 
be addressed by employing a combination of biochemical analyses such as co-
immunoprecipitation of NF-B and RUNX3 proteins, together with functional assays 
such as reporter gene assays. Recent studies have shown that the inhibition of NF-B 
in epithelial cells has an unexpected pro-inflammatory effects and contributes to 
carcinogenesis (Lind et al., 2004; Nenci et al., 2007; Pasparakis et al., 2002; van 
Hogerlinden et al., 1999). Such emerging evidence highlights the intricacies that exist 
within host immunity where the modulating role of RUNX3 on key NF-B targets 
could prove very significant. 
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During gastric carcinogenesis, host immune response and inflammation are 
often initiated by wounding of tissues due to pathogen invasion. Wound healing 
involves not only the clearance of microbes but also enhanced cell proliferation for 
tissue repair and the reconstitution of the barrier system. Failure to do so may perturb 
the homeostatic balance which leads to chronic inflammation, hyperproliferation and 
formation of neoplastic lesions (section 1.2.6); (Coussens and Werb, 2002). A major 
culprit for gastric inflammation and gastric cancer is H. pylori (Suerbaum and 
Michetti, 2002). The positive correlation observed for H. pylori infection and IL23A 
expression in this study implicates IL23A as a component of the innate host defense 
mechanism. This notion is further strengthen by the prolonged induction of IL23A by 
the CagA-positive strain of H. pylori, which confers a higher risk of gastric cancer and 
ulceration (Suerbaum and Michetti, 2002).  
In addition to the gastric epithelial cell-autonomous regulation, the balance of 
host immunity in vivo is delicately maintained by the communication between 
epithelial cells, immune cells and the surrounding stroma (Izcue et al., 2009; 
Shaykhiev and Bals, 2007). A growing body of evidence indicates a 
pathophysiological background for cancer is constituted by the impaired 
communication between immune and epithelial cells of the tissues (Shaykhiev and 
Bals, 2007). The observation that RUNX3-induced IL23A derived from AGS cells 
modulates T cells proliferation and differentiation point to a potential involvement of 
RUNX3/IL23A in the complex communication between epithelial and immune cells. 
In addition, AGS-derived IL23A was shown to modulate the production of IFN- by 
T cells suggests that it may promote the proliferation and differentiation of Type I 
helper T cells (TH1). In future studies, a detailed characterisation of the surface and 
intracellular markers expressed by the proliferating T cells fraction is necessary for 
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the identification of the specific subsets of T cells that respond to IL23A. Their 
identification will in turn enable the purification of the responsive subset of T cells to 
further elucidate the biological effect of gastric epithelial-derived IL23A. This should 
be complemented with assays based on a co-culturing of epithelial cells and immune 
cells, as it mimics the in vivo communication between these cell types that may 
further potentiate the effects of secreted IL23A (Bernhardt et al., 2010; Duell et al., 
2011). Lastly, future studies employing these approaches would be greatly advanced 
by the identification of the putative partner for IL23A. Given the body of evidence 
presented here, a proteomic approach using mass spectrometry can be employed to 
profile the secretome of AGS cells enriched with IL23A-specific antibody to reveal 
the identity of this putative cytokine. 
In addition to the data from human gastric cell lines, murine primary gastric 
epithelial cells were shown to express IL23a transcript upon TNF-treatment (Jason 
Koo, unpublished data). The conservation of this regulatory mechanism in both 
mouse and human strengthens its physiological relevance and produces an additional 
means for downstream investigation of the in vivo function of IL23a in mouse models. 
Of particular interest would be a stomach-specific knockout of IL23a to ascertain the 
in vivo role played by IL23a, which will also shed new light on the function of Runx3. 
In addition, H. pylori’s effects on IL23A in human gastric epithelial cell lines also 
await further validation through the use of murine Helicobacter infection models. 
Two strains of Helicobacter, H. felis and H. pylori have been proven to colonise 
mouse stomachs and lead to chronic inflammation (Chen et al., 1992; Ferrero et al., 
1995; Marchetti et al., 1995; Michetti et al., 1994). By establishing a model of 
Helicobacter infection, the role of IL23a in anti-bacteria immunity and inflammation 
in the stomach could be further established. Lastly, to demonstrate the functional 
132 
 
importance of RUNX1 and RUNX3 in the regulation of IL23A in vivo, a transgenic 
mouse model should be generated in which the Runx3-responsive element in IL23a 
promoter could be conditionally deleted using stomach-specific Cre/loxP 
recombination system.  
To complement the functional study of Runx1/3 regulation of Il23a in mice, 
the clinical significance of this relationship should also be established. This would 
include clinicopathological analysis of human gastric tissues by immunohistochemical 
(IHC) staining to demonstrate the expression of IL23A in the human gastric 
epithelium. Furthermore, as the loss of RUNX3 function has been reported in up to 
80% of gastric cancer cases (section 1.2.4), it will be of clinical relevance to 
investigate if the expression of IL23A in human samples correlates with that of 
RUNX3 expression, in normal and diseases states; and whether it co-occurs with the 
infiltration of leukocytes. Lastly, a comparison between the expression of RUNX3 
and IL23A in H. pyrori-positive and -negative gastric patients would provide further 
evidence for a role of this pathway in host response against this important gastric 
pathogen. 
In conclusion, the findings in this study reveal an immunological aspect of 
RUNX3 function in gastric epithelial cells through the direct regulation of IL23A and 
cooperation with TNF- and H. pylori. It suggests that the loss of RUNX3’s function 
during gastric carcinogenesis may impair the ability of gastric epithelial cells to 
produce IL23A as part of an innate host immune response against pathogen-induced 
inflammation. This would in turn result in ineffectual pathogen immunity, chronic 
inflammation and ultimately gastric neoplasia. As such, a comprehensive 
understanding of biological function of IL23A and the pivotal role of RUNX proteins 
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play may offer a novel therapeutic strategy in preventing H. pylori-induced gastric 
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